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1. Introduction 
 
1.1. Cellular composition and physiology of human mammary gland 
 
The mammary gland is positioned between the pectoralis major muscle and the 
nipple (Henrikson et al., 1997). The mammary gland is a paired, tubuloalveolar, 
exocrine gland which produces milk in females (Henrikson et al., 1997; Linzell and 
Peaker, 1971). The produced milk is collected in the nipple sinus and excreted in a 
response of infant’s suckling (Linzell and Peaker, 1971). The nipples are surrounded 
with sebaceous glands rich areola and represent the convergent point of mammary 
lobes, functional units of the adult mammary gland. It has been suggested that 
sebaceous glands positioned within the nipple areola and/or sweet glands might 
represent the evolutionary origin of the mammary glands (Oftedal, 2002). In human, 
primitive sebaceous glands and/or sweet glands evolved in 15-20 epithelial lobes 
which produce milk (Henrikson et al., 1997; Oftedal, 2002). During the course of 
mammary gland ontogeny, the mammary lobes arise from a primitive anlage, which 
undergoes series of morphological changes mainly postnatal (Radisky and 
Hartmann, 2009). The mammary gland reaches functional maturity at pregnancy 
during the process known as lactation when the mammary gland is composed of 
secretory epithelia (Borellini and Oka, 1989). 
The adult mammary gland is an inhomogeneous organ composed of epithelial 
derived ducts surrounded by connective tissue and immersed in the adipose tissue 
lobes (Figure 1 a) (Sheffield, 1988). Although the milk production and excretion in the 
mammary gland is accomplished by epithelial derived cells, various biological 
processes (i.e. mammary gland development, hypertrophy, involution) in the adult 
and developing mammary gland are regulated trough inter -cellular and -tissue 
interactions (Maller et al., 2010). 
The ratio between mammary cells of the epithelial and stromal origin is changing 
during the life time due to the continuous cycles of proliferation, differentiation, 
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lactation and regression of mammary gland epithelial component (Parmar and 
Cunha, 2004). During the puberty, the first changes occur in the growth of the stromal 
tissue. It has been suggested that stromal proliferation serves to inhibit the growth of 
the epithelial compartment (Howard and Gusterson, 2000). While the mammary fat-
pad of non-pregnant females is largely assembled of the adipose tissue, the adipose 
compartment is gradually substituted by epithelial tissue, blood vessel and 
connective tissue during the pregnancy (Borellini and Oka, 1989; Russo and Russo, 
2004) .  
Moreover, the adult mammary gland is well-vascularized organ and supplied with 
wide lymph drainage, which is relevant to oncology because the breast cancer 
metastases develop on the distant sites due to the dissemination of cancer cells via 
blood and lymph vessels (Howard and Gusterson 2000; Eccles, Paon et al. 2007; 
Andres and Djonov 2010; Vermeulen, van Golen et al. 2010). 
 
Figure 1. Human breast anatomy and the cellular organization of a TDLU.  (A) Human breast is a 
complex organ composed of tissue of diverse origin. 1) Chest wall; 2) Pectoralis muscles; 3) Mammary 
gland ducts and lobules; 4) Nipple; 5) Areola mammae; 6) Lactiferous duct; 7) Adipose tissue; 8) Skin. 
(B) Mammary gland duct is composed of myoepithelial cells, luminal cells, secreting (cap) cells and 
mammary stem and progenitor cells. Picture modified from (Tiede and Kang, 2011; Wikipedia, 2012). 
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Deregulation of the both stromal and epithelial cell growth may cause breast 
hypertrophy, which is manifested in the abnormal breast sizes (macromastia or 
gigantomastia). The hypertrophy usually develops during puberty or at menopause 
(Dancey et al., 2008; Dehner et al., 1999). Following the medical care policy, the 
patients diagnosed with macromastia or gigantomastia undergo breast reduction 
surgery due to the physical, aesthetic or psychophysical difficulties (Nguyen et al., 
2008). Tissue specimens of patients experiencing breast reduction can be used for 
the experimental purposes (Dontu et al., 2003a). 
Mammary lobes of an adult gland consist of a collection of acini arising from terminal 
ducts embedded in intralobular stromal tissue (Parmar and Cunha, 2004). Terminal 
duct lobular units (TDLU) are considered as the functional units of the mammary 
gland. Each duct is composed of the two major cell types: myoepithelial and luminal 
cells (Figure 1 b). A layer of myoepithelial cells is found positioned directly below the 
basal membrane. Myoepithelial cells are characterized by the expression of the alpha 
smooth muscular actin and cytokeratins 5 and 14 (Stingl et al., 2005). Contractions of 
the myoepithelal cells enable milk excretion. Above the myoepithelal cell layer 
towards the lumen is the inner layer of luminal cells subdivided into ductal luminal 
cells, which line inside of the ducts, and alveolar luminal cells, which arise during the 
pregnancy and secrete milk (Visvader and Lindeman, 2011). The majority of the cells 
(>90%) found within the mammary ducts are differentiated luminal and myoepithelial 
cells (Chepko and Smith, 1997; Stingl et al., 2005). 
1.2. The mammary gland development 
 
The mammary gland development occurs in three distinct and differentially regulated 
stages: embryonic, pubertal and adult (Gjorevski and Nelson, 2011; Howard and 
Gusterson, 2000). Embryonic development and extensive proliferation and 
differentiation during each pregnancy cycle are enabled by the presence of mammary 
stem cells (Dontu et al., 2005; Van Keymeulen et al., 2011). Moreover, the regulation 
of developmental and differentiation processes involve an ample variety of hormones 
and growth factors such as estrogen, progesterone, and prolactin that drive primitive 
mammary stem cells towards differentiated functional cells (Henrikson et al., 1997; 
Stingl, 2011; Tiede and Kang, 2011).  
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Development of the human mammary gland begins at week 5 of the embryonic 
development. The first developmental sign is the formation of the milk streak, 
thickening in the ectoderm, extending from the axilla to the groin. During week 6 and 
7 the milk streak develops to the mammary crest which later develops into the 
epithelial bud (Gusterson and Stein, 2012; Howard and Gusterson, 2000). Cells 
expressing some of the myoepithelial cell markers are observed in this period of 
embryonic development (Van Keymeulen et al., 2011). Embryonic development ends 
with a formation of a series of blind-ended tubes, with bulbous tips, well defined 
lobules and terminal duct lobular units, similar to those observed in the adult 
mammary gland. Shortly after birth, the mammary gland undergoes involution similar 
to the observed process in the post-menopausal breast (Anbazhagan et al., 1991; 
Gusterson and Stein, 2012).  
The infant’s mammary gland development after involution process at birth follows the 
overall body development until puberty when the swift development in females starts. 
Nevertheless, while the knowledge about the embryonic human mammary gland 
development is still incomplete due to the lack of tissue specimens, the 
developmental stages and processes in the animal models increase significantly our 
knowledge during the last decade pinpointing key steps of early development and 
involved signaling networks (Hens and Wysolmerski, 2005; Van Keymeulen et al., 
2011). 
The mammary gland development in human is hormonally regulated as many other 
processes of the pubertal maturation (Sternlicht et al., 2006; Stingl, 2011). The 
hormonal regulation starts before the first menstrual cycle when estrogen receptors 
are detectable in the low percent of the luminal cells (Gusterson and Stein, 2012; 
Sternlicht et al., 2006). Development of the TDLU is characterized by the 
development of the end buds and lateral buds (Russo and Russo, 2004). 
Unfortunately, the knowledge about the mammary gland development during pre -
pubertal and pubertal age is not yet sufficient to prove any of the proposed models 
due to the low number of the analyzed samples. Moreover, little is known about the 
molecular mechanism of the stromal influence during development while it has 
become clear that stromal cells actively influence and shape many of the mammary 
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gland abnormalities related to the developmental processes (Bonafe et al., 2012; Cirri 
and Chiarugi, 2012). 
1.3. Cellular hierarchy in the normal mammary gland   
 
The majority of cells found within adult mammary ducts are differentiated luminal and 
myoepithelial cells (Chepko and Smith, 1997; Stingl et al., 2005). Myoepithelial cells 
are in direct contact with the basal membrane and they are cells responsible for the 
ductal contraction and milk circulation in a response to oxytocin (Sternlicht et al., 
2006). Luminal cells are orientated towards lumen and build TDLU. During lactation, 
a sub-type of luminal cells located in the alveoli and hence named alveolar cells 
produce milk. In addition to these differentiated cell types, the adult mammary gland 
contains stem cells and progenitor cells (Figure 2). Thus, the mammary gland is a 
hierarchically structured organ (Stingl et al., 2005; Visvader and Lindeman, 2011). 
The presence of the undifferentiated cells within the adult gland enables mammary 
gland maturation and cyclic differentiation processes during the adult life (Stingl et al., 
2006). 
 
Figure 2. Hierarchical organization of the mammary gland. The adult mammary gland contains 
primitive adult stem cells which are able to reconstitute functional mammary gland. Figure is modified 
from the ref. (Visvader and Lindeman, 2011).   
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The adult mammary gland reaches functional maturity at pregnancy when branching 
TDLU are formed trough multi- step sequences of proliferation and differentiation 
processes (Sternlicht et al., 2006). Each pregnancy cycle ends with controlled 
reduction of the epithelial cell compartment by apoptosis (Radisky and Hartmann, 
2009). These cyclical bursts of proliferation and subsequent apoptosis recur also 
during each menstrual cycle (Russo and Russo, 2004) and are enabled by the 
existence of the cells with differentiation and self-renewal ability, adult stem and 
progenitor cells (Dontu et al., 2003b).  
The existence of a multipotent cellular type within the adult mammary gland able 
to reconstitute functional adult mammary gland has been shown by numerous 
independent experiments. The first mammary transplantation studies in the late 
1950’ies by DeOme and colleagues suggested that the adult mammary gland 
contains a cell type able to reconstitute the mammary gland of the adult mice (Daniel 
et al., 1971; Deome et al., 1959). Furthermore, the engraftment of human tissue 
pieces into pre-cleared mammary fat-pads of immunodeficient mice suggested the 
existence of cells able to reconstitute the functional human mammary gland 
(Kuperwasser et al., 2004). The presence of the adult mammary stem cells was 
proven by Shakelton and colleagues who were able to reconsti tute a functional 
mouse mammary gland form a single mammary cell (Shackleton et al., 2006). 
However, although today we have experimental evidences of adult mammary stem 
cells existence, the main problem for the study of mammary gland development and 
pathophysiology remained the isolation and molecular and functional characterization 
of the adult mammary stem and progenitor cells. 
Although several subpopulations of mammary cells have been described, the 
existence and precise molecular profile of adult mammary stem cells is still 
intensively discussed (Keller et al., 2011; Stingl et al., 2005).  
1.4. Isolation of the mammary stem and progenitor cells  
 
Stem cells are defined as cells capable for multi-lineage differentiation and self-
renewal (Luo et al., 2010; Smalley and Ashworth, 2003). It has been suggested that 
understanding mammary gland biology, development and pathophysiology mostly 
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depends on our ability to isolate, grow and manipulate undifferentiated cell types 
(Dontu et al., 2003a; Smalley and Ashworth, 2003). Therefore, the enormous efforts 
have been invested in the development of different strategies for the isolation and 
characterization of adult stem and progenitor cells.  
1.4.1. Isolation of the mammary stem and progenitor cells based on 
marker expression 
 
Scientists in mammary stem cell research were initially inspired by studies in the field 
of hematopoiesis and tried to develop various assays that help enrichment of the 
mammary stem and progenitor cells (Alvi et al., 2002; Eirew et al., 2008; Stingl et al., 
2005).  
One of the first methods for the isolation of stem and progenitor cells was based on 
the observation that due to over-expression of transmembrane transporter proteins 
stem cells are able to exclude vital marker dyes (Smalley and Ashworth, 2003). The 
so-called “side-population” remained unstained by DNA-binding dyes due to its ability 
to pump out the dye while more differentiated progenies were not able to exclude the 
DNA-binding dye (Charafe-Jauffret et al., 2009). Whereas the first reports 
convincingly demonstrated enrichment of stem cells and cancer stem cells (Alvi et al., 
2002), later reports indicated many inconsistencies which hindered the experimental 
reproduction of the results and their validation (Montanaro et al., 2004). 
On the other hand, empirical testing of surface marker combination enabled the 
definition of markers used for Fluorescence Activated Cell Sorting (FACS) 
methodology to identify and isolated adult stem and progenitor cells (Charafe-Jauffret 
et al., 2009; Ginestier et al., 2007a; Stingl et al., 2005). Thus, the cellular types 
defined by their functional characteristics, luminal and myoepithelial cells are 
described by the following cellular markers: 1) differentiated luminal cells are CK14-
/CK18+/CK19+ and MUC1+ cells, while 2) myoepithelial cells are characterized as 
CK14+/SMA+ and CD10+ cells. The luminal progenitor cells are defined as as 
MUC1+/CD133+/EpCAM+/CD49f+/CD10-/THY-, while the myoepithelial progenitors 
express the marker following marker combination MUC1-/CD133-
/EpCAM+/CD49f+/CD10+/THY+ (Bartek et al., 1990; Snedeker et al., 1991; Stingl et 
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al., 1998; Stingl et al., 2001; Stingl et al., 2005). It is important to say that the function 
of these markers is often unclear. Unfortunately, many attempts to define adult stem 
and progenitor cells based on marker expression led to inconsistent conclusions. 
Keller et al. used healthy mammary tissue specimens to define cellular populations 
within the adult mammary gland. They found that both, EpCAM+ and CD10+ 
population contain differentiation potential (Keller et al., 2011). On the other hand, the 
mentioned study (Keller et al., 2011) is opposed to the observation that mammary 
repopulating units were found to reside in EpCAM-/low phenotype (Eirew et al., 
2008).  
Taken together, our inability to isolate adult stem and progenitor cells by marker 
expression hampered the attempts for their perspective characterization and 
manipulation. Nevertheless, the alternative approaches demonstrated that the 
isolation and characterization of the adult mammary stem and progenitor cells is 
possible. 
1.4.2. Mammospheres- enriched population of adult mammary stem and 
progenitor cells 
 
Based on the neural stem cell research assays, Gabriela Dontu and colleagues 
applied a cell culture system for neural stem cells to propagate undifferentiated cells 
isolated from the adult mammary specimens (Dontu et al., 2003a). Basis of the 
mammosphere assay was the observation that rare undifferentiated cells survive 
anchorage independent conditions and proliferate to form multi-cellular spheroids 
while most of the cells isolated from mammoplasty tissue specimens underwent 
anoikis when grown under ultra-low attachment conditions. It was suggested that 
inability of differentiated cells surviving anchorage independent conditions  underlies 
the selective propagation of adult stem and progenitor cells  (Dontu and Wicha, 2005).  
Mammospheres are highly enriched in undifferentiated cells, as demonstrated by the 
ability of single cells propagated as mammospheres to generate multi-lineage 
colonies, which is not the case in the presence of serum or when propagated on a 
collagen substratum (Dontu et al., 2003a; Liu et al., 2008). The primary 
mammospheres contain eight times more bi-lineage progenitor cells compared to the 
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tissue of origin. The secondary and later-passaged mammospheres consist of 
virtually 100% bi-potent progenitors (Dontu et al., 2003b; Dontu and Wicha, 2005). 
Moreover, mammospheres form complex structures in reconstituted 3-D culture 
systems in Matrigel©, resembling the observed morphology of the functional adult 
mammary gland (Dontu et al., 2003a).  
In vivo experiments indicated that the secondary mammospheres are able to 
differentiate in complex ducto-acinar structures comparable to the TDLU when 
inoculated in NOD/scid mice, immunodeficient mice (Liu et al., 2006; Liu et al., 2008; 
Pece et al., 2010).  
Growth and enrichment of the mammary stem and progenitor cells as spherical 
colonies was shown to be currently the most efficient way for the enrichment and 
propagation of the mammary stem and progenitor cells (Dontu et al., 2003a; Luo et 
al., 2010). 
1.4.3. Isolation of the stem and progenitor cell fractions by functional 
properties 
 
In 2010, Pece and colleagues developed another experimental strategy for stem cell 
enrichment of a pre-selected population of the mammary stem and progenitor cells. 
The mammary stem and progenitor cells were propagated under anchorage 
independent conditions. After the secondary mammospheres were formed stem and 
progenitor cells were selected on a basis on their functional characteristics (Pece et 
al., 2010).  
The mammary stem cells are asymmetrically and slow dividing cells , which upon cell 
division give rise to two daughter cells; one is the self-renewed stem cell, while the 
other cell represents a progenitor cell (Harmes and DiRenzo, 2009; Smalley and 
Ashworth, 2003). The discrimination between two daughter cells is based on their cell 
division rates, stem cells are slower dividing cells compared to progenitor cells (Pece 
et al., 2010).  
It was shown that single mammospheres can reconstitute the functional 
mammary gland in vivo and that mammospheres arise from single cells. Thus, the 
mammospheres are groups of cells, which arise from a single adult stem cell (Dontu 
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et al., 2003a; Shackleton et al., 2006). The isolation of the adult stem cells by Pece 
and colleagues relies on the following approach: If the cellular membrane of the cells 
propagated under anchorage independent conditions is labeled by a fluorescent 
marker, and the dye is equally distributed to the daughter cells  upon each cellular 
division, then due to the slow cycling frequency of the stem cells, the label retaining 
cells represent the mammosphere stem cell, while the fast cycling cells within a 
mammosphere become quickly unlabeled and represent daughter cells (Lanzkron et 
al., 1999). Therefore, during the growth of a mammosphere, the rare quiescent/slowly 
dividing mammary stem cells retain dye, while the bulk of population derived from the 
proliferation of the progenitors progressively lose it by di lutions (Pece et al., 2010).  
1.5. Differentiation ability of mammary stem and progenitor cells 
 
Stem cells are characterized by the ability to self-renew and generate daughter cells 
that can form all the differentiated cell types found within the mature tissue (Smalley 
and Ashworth, 2003). Differentiation ability of the adult mammary stem and 
progenitor cells can be analyzed under in vitro and in vivo differentiation conditions 
(Eirew et al., 2008; Liu et al., 2008; Weaver and Bissell, 1999).  
1.5.1. In vitro differentiation of mammary stem and progenitor cells 
 
The human mammary gland develops and functions in a complex micro-environment 
composed of different cell types and an intricate network of extracellular molecules. It 
has been suggested that micro-environment influences epithelial cell homeostasis 
and differentiation (Nelson and Bissell, 2006) and therefore in the previous years 
different experimental strategies have been applied to unravel the micro-
environmental influences on the cell fate of mammary cells (Campbell et al., 2011; 
Weaver and Bissell, 1999).  
The most frequently applied matrix to study in vitro differentiation is Matrigel©, a 
reconstituted basement membrane of mice developing Engelbreth-Holm-Swarm 
sarcomas (Lee et al., 2007). The differentiation of adult human mammary stem and 
progenitor cells in such Matrigel© matrices results in a formation of (i) acinar 
structures resembling terminal end-buds of human mammary glands; (ii) TDLU- 
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complex terminal ductal-lobular structures and (iii) single cells which are not able to 
propagate (Dontu et al., 2003a). Therefore, the in vitro differentiation strategies in 
Matrigel© provide possibility to study development in a relevant micro-environment.  
Moreover, the Matrigel© is often used in cancer biology. One of the most important 
feature of malignancies is cellular invasion which enables tumor cell dissemination 
from the primary site and subsequent metastasis development (Hanahan and 
Weinberg, 2011). Cell propagation in Matrgel© can give information about the 
tumorigenic ability of the analyzed cells in a relevant milieu because it has been 
observed that the extracellular matrix can control the function of cells with aberrant 
genotype to some extent (Lee et al., 2007; Nelson and Bissell, 2006).  
1.5.2. In vivo models for mammary stem and progenitor cell 
differentiation 
 
Definitive evidence for the existence of adult stem cells within mammary gland is 
given by in vivo studies (Eirew et al., 2008).  
The presence of stem cells within adult mouse mammary gland was 
demonstrated by reconstitution of normal mammary gland  by a single cell 
(Shackleton et al., 2006), but the presence of adult stem cells within human 
mammary gland could not be shown due to the technical obstacles. 
The first attempts to propagate normal human cells in mouse mammary fat-pad were 
not successful (Outzen and Custer, 1975) mainly because of the inability of normal 
human mammary cells to survive in recipient mice due to (i) the host immune system 
and (ii) micro-environmental differences between human and murine mammary gland  
(Howard and Gusterson, 2000; Proia and Kuperwasser, 2006). The problem of the 
immune rejection was circumvent by utilization and development of immune-deficient 
mice such as NOD.CB17-Prkdcscid/J (Kuperwasser et al., 2004). The problem of the 
micro-environmental difference between human and murine mammary gland is in 
some reports overcame by engraftment of collagen plugs containing human 
mammary stem and progenitor cells subcutaneously or beneath the renal capsule 
(Eirew et al., 2008; Parmar et al., 2002), but such approaches do not consider the 
endocrine signaling of the adult mammary gland which is important for the gland 
development and regulation (Borellini and Oka, 1989; Kuperwasser et al., 2004). 
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Development of the orthotopic xenograft mouse models was enabled by 
“humanization” of the mouse mammary fat-pad by human immortalized fibroblasts 
(Kuperwasser et al., 2004; Proia and Kuperwasser, 2006). The recent progress made 
in isolation and propagation of human mammary stem and progenitor cells (i.e 
mammosphere culture) enabled study of normal and malignant mammary cells 
development and growth in immune-deficient mice (Liu et al., 2006; Liu et al., 2008; 
Pece et al., 2010). However, reconstitution of the human mammary gland in mice by 
“humanization” protocol (Liu et al., 2006; Proia and Kuperwasser, 2006) has shown 
many technical difficulties and risks for reproducibility due to sensitivity of the 
experimental approach what imposed the need for the development of more efficient 
orthotopic xenograft models. 
1.6. Breast cancer 
 
Breast cancer accounts as the most frequent cancer type among women. In 2008, 
breast cancer caused 458 503 deaths worldwide (WHO, 2008). The main culprit of 
the associated mortality is metastasis development at secondary, distant sites (Jemal 
et al., 2008). 
Currently applied therapies against breast cancer depend on pathophysiological 
features determined by various methods (Downs-Holmes and Silverman, 2012). The 
frequently applied TNM classification subdivides breast cancer based on tumor size 
(T), number of lymph nodes containing infi ltrated tumor cells (N) and presence of 
distant metastasis (M). The TNM classification is often supplemented by the 
morphological criteria, such as the differentiation grade of the observed tumor which 
indicates the probability of tumor recurrence (Bundred, 2001). The tumors may 
display characteristics of the differentiated mammary gland and therefore be 
subdivided into ductal carcinomas or lobular carcinomas. The grade is a summary 
score of values given to the mitotic index, percentage of tubular structures and 
nuclear pleomorphism (Elston and Ellis, 1991). Tumors with scores from 3 to 5 are 
well differentiated (grade 1), from 6 to 7 are moderately differentiated (grade 2), and 
8 to 9 (grade 3) are poorly differentiated (Cianfrocca and Goldstein, 2004; Elston and 
Ellis, 1991). Grade 2 tumors make 50- 75% of all diagnosed breast tumors (Elston 
and Ellis, 1993; Parham et al., 1992) and show characteristics between differentiated 
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and poorly differentiated histological grades 1 or 3 status (with a low or high risk of 
recurrence, respectively) and therefore, to increase precision of cancer grades, 
further classification of the grade 2 tumors was preformed based on their gene 
expression. The applied re-classification divided the patients into two groups, groups 
with high versus low risk of recurrence (Sotiriou et al., 2006).  
Poorly differentiated tumors exhibit the characteristics of the undifferentiated 
mammary cells. Hence, it has been suggested that poor differentiation of mammary 
cancers reflects the expression of stem-like traits (Ben-Porath et al., 2008). The 
reasoning raised the interest in studies of the mammary stem cell biology. 
1.7. Cancer stem cell concept 
 
Hyper-proliferation of cancer cells combined with genetic instability in the primary 
tumors results in their cellular heterogeneity (Hanahan and Weinberg, 2011). 
However, the cellular heterogeneity of the primary tumor is not only reflected in 
genetic differences among tumor clones, but also in functional hierarchy within the 
tumor cells (Ginestier et al., 2007a; Mani et al., 2008). 
Cancer stem cells (CSC) are defined as tumor clones able to grow tumors in 
animal hosts and differentiate into non- CSC (Clarke et al., 2006). Rare but potent, 
CSC give rise to all other cancer cell types detected within the tumor and contribute 
to an invasive phenotype observed in metastatic breast tumors (Rudland, 1987; 
Sheridan et al., 2006). The current CSC concept indicates that disease relapses and 
later progression is largely due to the intrinsic therapy resistance of CSC (Gupta et 
al., 2009). The CSC concept does not suggest that the target cell of malignant 
transformation is a mammary stem cell, but the CSC possess characteristics of the 
normal counterparts (Bjerkvig et al., 2005).  
The CSC concept further holds that successful eradication of a cancer is only 
possible if the applied therapies are able to target CSC. The analysis of CSC 
expression profi les showed that CSC utilize molecular pathways that are frequently a 
part of a stem cell program and moreover are correlated with the histopathological 
grading (Palmer et al., 2012). Therefore, it may be a plausible hypothesis that 
knowledge about the signaling networks governing the stem cell phenotype will also 
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improve our understanding of tumor biology and help to design novel targeted 
therapies. 
 
Figure 3. The adult mammary stem cells and breast cancer stem cells share certain 
characteristics. The cancer stem cells might arise either from specific adult stem or progenitor cells, 
but stem-like phenotype acquisition by the differentiated cells should be considered (Bjerkvig et al., 
2005).  
1.8. Interleukin 6 and breast cancer 
 
Interleukin 6 (IL6), a multifunctional cytokine, plays a role in p ro- and anti-
inflammatory response and has a primary function in the pathophysiology of many 
diseases such as rheumatoid arthritis, Castleman’s dieses and cancer (Grivennikov 
and Karin, 2008; Kishimoto, 2005).  
IL6 signaling is mediated via IL-6 binding to IL6 receptor (IL6R) which induces homo-
dimerization of the signal transducing receptor gp130 which leads to activation of 
multiple signaling networks (Keller et al., 2002). IL6 signaling is responsible for 
regulation of various biological processes as cell survival, apoptosis and proliferation 
in murine hematopoietic stem cells, hepatocytes and MCF7 breast cancer cell line 
(Gotze et al., 2001; Peters et al., 1998a; Sansone et al., 2007).  
IL6 signals via a heterodimeric IL6/IL6R/gp130 complex, whose engagement triggers 
activation of Janus (JAK) kinases, and the downstream effectors STAT3, SHP-2/Ras, 
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NF-κB and PI3K/Akt (Kishimoto, 2005). The IL6/IL6R/gp130 complex can be build by 
either utilization of the membrane bound IL6R or the soluble form of IL6R (sIL6R) in 
the process known as IL6 trans-signaling (Peters et al., 1998b; Taga et al., 1989). 
The effect of the IL6 signaling on breast cancer was elaborated in various systems 
(Iliopoulos et al., 2011; Korkaya et al., 2012; Sansone et al., 2007), but in all of the 
mentioned reports it is not clear whether the IL6 signaling is maintained via 
membrane bound or soluble IL6R which is of high therapy design importance 
because high levels of sIL6R can be found in human sera. 
 
Figure 4. IL6 signaling pathway. IL6 signaling pathway is triggered by dimerization of the IL6 and 
IL6R. IL6-IL6R complex binds to gp130 and form a complex of 6 members complex (2 x IL6, 2x IL6R 
and 2x gp130). The complex triggers the signaling pathway via intracellular domain of gp130. IL6 
signaling is madiated via complex signaling networks (i.e. JAK/STAT3, PI3K/Akt/mTOR, Raf/Mek/Erk). 
The figure is modified from the reference (CellsignalingTechnology, 2012). 
Increased levels of IL6 in sera of breast cancer patients correlate with poor disease 
outcome and reduced prognosis (Bachelot et al., 2003). This might be a 
consequence of an overall IL6 influence on the growth rate of the primary tumor 
(Korkaya et al., 2012), but the exact mechanisms of these action is not yet 
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elucidated. Possible mechanism of action might be via CSC as deduced from the 
studies in the MCF7 cell line. Activation of the IL6 signaling induced self- renewal, 
hypoxia survival, and invasiveness of MCF7 cell line derived mammospheres 
(Sansone et al., 2007). Additionally, IL6 signaling has been proposed to regulate the 
conversion of the non- stem cancer cells into cancer stem cells (Iliopoulos et al., 
2011) but this observation needs further clarification. 
 
 
Figure 5. IL6 signaling in cancer cell. IL6 signaling in the cancer cells is maintained via IL6 secretion 
by various non-epithelial cells types. The IL6 signaling influences various biological processes 
enabling cancer cell survival, proliferation and self-renewal (Grivennikov and Karin, 2008; Korkaya et 
al., 2011). 
Present knowledge suggests that IL6 signaling in cancer is maintained trough IL6 
expression by cancer associated fibroblasts, macrophages and various different cell 
types (Bonafe et al., 2012) while it is not much known about the effect and sources of 
the sIL6R.  
Having in mind the importance of the IL6 signaling the aim of this work was to further 
elaborate the effect of the IL6 trans-signaling in normal and malignant breast stem 
and progenitor cells. 
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1.9.  The aim of the work 
 
The mammary gland is hierarchically structured organ containing cellular types of 
various differentiation stages. The mammary gland development and extensive 
proliferation and differentiation during each pregnancy cycle are enabled by the 
presence of the adult mammary stem cells which phenotype is regulated by 
activation of stem signaling pathways. These signaling pathways are activated as a 
result of the dynamic interaction between mammary cells and micro-environment. 
Deregulation of stem cell signaling pathways has been suggested to drive breast 
cancer by maintaining cancer stem cells (CSC), cells which give rise to all other 
cancer cell types detected within the tumor and contribute to an invasive phenotype 
observed in metastatic breast tumors. As normal stem cells, CSC interact with micro-
environment and these interactions involve inflammatory cytokines such as 
Interleukin 6 (IL6). 
 
The aims of the proposed PhD thesis were: 
 
1)  To address how IL6 signals in normal mammary stem and progenitor cells , 
2)  To assess the effects of IL6 signaling in regulation of normal mammary stem and 
progenitor cell phenotype, 
3) To assess the ability of cellular cooperation in triggering IL6 trans-signaling in 
mammary gland, 
4)  To evaluate the effects of the IL6 trans-signaling in CSC phenotype.
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2. Materials and Methods 
2.1. Materials 
 
2.1.1. Reagents, solutions and cell culture media 
 
Reagents, solution and cell culture media used in this work are listed in the following 
tables. 
 
 Reagents Company 
1 AB-Serum Bio-Rad, Dreieich 
2 Acetic acid Merck, Darmstadt 
3 Agarose Sigma-Aldrich, USA 
4 Ampicillin AppliChem GmbH, Darmstadt 
5 B27 Invitrogen, USA 
6 BCIP/NBT (AP color reagent) BioRad, Munich 
7 Basic fibroblast growth factor (bFGF) Sigma-Aldrich, USA 
8 bio-dUTP, 1 mM Roche, Penzberg 
9 Bromphenol blue Sigma-Aldrich, USA 
10 Bovine serum albumin (BSA), 20 mg/ml Roche, Penzberg, Mannheim 
11 Bovine serum albumin (BSA), 30% Biotest, Dreieich 
12 Chloroform Sigma-Aldrich, USA 
13 Chloroquine Sigma-Aldrich, USA 
14 Cholera toxin Sigma-Aldrich, USA 
15 Collagenase Sigma-Aldrich, USA 
16 DAPI Roche, Penzberg 
17 dATP, 100 mM GE Healthcare, UK 
18 dCTP, 100 mM GE Healthcare, UK 
19 DEPC-H2O Invitrogen, USA 
20 dGTP, 100 mM GE Healthcare, UK 
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21 Dichlorodimethylsilane, 2% in 1,1,1-
trichlorethane 
Merck, Darmstadt 
22 Diluent C Sigma-Aldrich, USA 
23 Disodium phosphate Sigma-Aldrich, USA 
24 Ditiotreitol (DTT), 0.1 M Invitrogen, USA 
25 DMEM Pan-Biotech, Aidenbach 
26 DMEM/F12 Pan-Biotech, Aidenbach 
27 DNA ligase T4, 5 U/μl Roche, Penzberg 
28 DNA polymerase PanTaq, 5 U/μl Pan Biotech, Aidenbach 
29 DNA polymerase Taq, 5 U/μl Roche, Penzberg 
30 DNA polymerase 
Thermo Sequenase (TS), 32 U/μl 
GE Healthcare, UK 
31 DNA-Ladder 1kb Invitrogen, USA 
32 DNase I, 2000 U/mg Roche, Penzberg 
33 dNTPs, 100 mM GE Healthcare, UK 
34 DSL peptide Research Genetics, USA 
35 dTTP, 100 mM GE Healthcare, UK 
36 EB buffer – QIAquick PCR Purification 
Kit 
Qiagen, Hilden 
37 EDTA Sigma-Aldrich, USA 
38 Eosin Sigma-Aldrich, USA 
39 Epidermal growth factor (EGF) Sigma-Aldrich, USA 
40 Ethanol, absolute J.T.Baker, Griesheim 
41 Ethidium-bromide, 1% Fluka, Sigma-Aldrich, USA 
42 Eukitt O. Kindler GmbH, Freiburg 
43 Fetal bovine serum (FBS) Sigma-Aldrich, USA 
44 Fetal bovine serum (FBS) Pan Biotech, Aidenbach 
45 Formaldehyde Merck, Darmstadt 
46 Formamide Merck, Darmstadt 
47 Formamide, deionized Sigma-Aldrich, USA 
48 Gentamicin Sigma-Aldrich, USA 
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49 H2O, for HPLC Merck, Darmstadt 
50 Hank’s salt solution Biochrom, Berlin 
51 Hematoxylin Ventana, USA 
52 Heparin Sigma-Aldrich, USA 
53 HEPES, 1M Sigma-Aldrich, USA 
54 Hyaluronidase Sigma-Aldrich, USA 
55 Hydrochloric acid, 37% J.T. Baker, Griesheim 
56 Hydrocortisone Sigma-Aldrich, USA 
57 Igepal CA-630 Sigma-Aldrich, USA 
58 Insulin Sigma-Aldrich, USA 
59 Interleukin 6 Sigma-Aldrich, USA 
60 Isopropanol Fluka, Sigma-Aldrich, USA 
61 L-Glutamine, 200 mM Pan-Biotech, Aidenbach 
62 Magnesium-chloride Sigma-Aldrich, USA 
63 Matrigel© BD Biosciences, Heidelberg 
64 MEBM Lonza, USA 
65 Methanol Merck, Darmstadt 
66 Mineral oil Sigma-Aldrich, USA 
67 Mouse serum DAKO, Hamburg 
68 mTRAPtm kit Active Motif, Japan 
69 Sodium acetate, 2M  pH 4 Calbiochem, Hamburg 
70 Sodium citrate Applichem, Darmstadt 
71 NEB buffer 1 New England Biolabs, USA 
72 NEB buffer 2 New England Biolabs, USA 
73 NEB buffer 3 New England Biolabs, USA 
74 NEB buffer 4 New England Biolabs, USA 
75 N-Laurylsarcosin Sigma-Aldrich, USA 
76 Parablast embedding medium (Paraffin) Sigma-Aldrich, USA 
77 Penicillin/Streptomycin, 10 U/μl Pan-Biotech, Aidenbach 
78 Percoll GE Healthcare, UK 
79 Peroxidase Blocking Solution DAKO, USA 
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80 Phytohemagglutinin, M form (PHA-M) Invitrogen, USA 
81 PolMix polymerase – Expand long 
template PCR system, 5 U/μl 
Roche, Penzberg 
82 Polybrene Sigma-Aldrich, USA 
83 Poly-HEMA Sigma-Aldrich, USA 
84 Potassium acetate, 5 M Sigma-Aldrich, USA 
85 Potassium chloride (KCl) Sigma-Aldrich, USA 
86 Potassium chloride (KCl), 1 M Fluka, Sigma-Aldrich, USA 
87 Potassium digydrogen phospate 
(KH2PO4) 
Merck, Darmstadt 
88 Propidiumiodid Sigma-Aldrich, USA 
89 Puromycin Sigma-Aldrich, USA 
90 Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe 
91 RPMI 1640 Pan-Biotech, Aidenbach 
92 β-Mercaptoethanol Carl Roth GmbH, Karlsruhe 
93 Trisodium citrate dihydrate Merck, Darmstadt 
94 Trypan blue, 0.4% Sigma-Aldrich, USA 
95 Tris(hydroxymethyl)-aminomethan 
(TRIS) 
AppliChem, Darmstadt 
96 Tris-acetate Sigma-Aldrich, USA 
97 Tris-HCl (pH 8), 1M Sigma-Aldrich, USA 
98 tRNA, 100 mg Roche, Penzberg 
99 Trypsin neutralization solution Sigma-Aldrich, USA 
100 Trypsin/EDTA, 10x Trypsin, 0.5% + 
EDTA, 0.2% in 1x PBS 
PAA, Austria 
101 Tween 20 Sigma-Aldrich, USA 
102 Ultra Puretm Herring sperm DNA 
solution 
Invitrogen, USA 
103 UltraPureTM DEPC- Water Invitrogen, USA 
104 Xylol Roth, Karlsruhe 
105 Zeocin Invitrogen, USA 
 
2. Materials and Methods 
 
22 
 
2.1.2. Antibodies 
 
 Antibody Company Clone Concentration 
1 Biotin anti-human 
CD126 (IL-6Rα) 
Biolegend, USA UV4 0,5 mg/ml 
2 Mouse IgG1, κ-
Isotype control 
Biolegend, USA MOPC-
21 
0,5 mg/ml 
3 Monoclonal anti-
human IL6 blocking 
antibody 
Sigma-Aldrich, 
USA 
6708.11 1,5 µg/ml 
4 Anti-human 
cytokeratin 18 
Chemicon CK2 20 µg/ml 
5 Anti-IL6R (FITC) Abcam B-R6 1 mg/ml 
 
 
2.1.3. The composition of prepared buffers, media and solutions 
 
 Solutions, Buffers and Media Composition 
1 Carnoy Fixative 7,5 ml methanol 
2,5 ml acetic acid 
2 Cell culture medium RPMI medium without L-
glutamine 
10% FCS 
200 U/mL penicillin 
200 U/mL streptomycin 
2 mM L-glutamine 
3 DAPI solution 10 µg/ml DAPI 
4x SSC / 0,2% Tween-20 
4 Hematoxylin solution 2 g hematoxylin 
0,4 g sodium iodide 
100 g potassium aluminium 
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sulfate 
100 g chloral hydrate 
2 g citric acid 
5 LB (liquid broth) 1% NaCl 
1% tryptone 
5% yeast extract 
pH  7,0 
6 Mammosphere medium 49 ml MEBM 
1x B27 
10 ng/ml EGF 
10 ng/ml bFGF 
4 µg/ml heparin 
7 Medium for the HME cell lines DMEM/F12 
10% FCS 
200 U/ml penicillin 
200 U/ml streptomycin 
10 ng/ml EGF 
0,5 µg/mL hydrocortisone 
10 µg/mL insulin 
8 Medium for the MCF7 and MDA-MB-
231 cell lines 
DMEM/F12 
10% FCS 
200 U/ml penicillin 
200 U/ml streptomycin 
2 mM L- glutamine 
9 Mammary tissue digestion medium DMEM/F12 
1% HEPES 
200 U/ml penicillin 
200 U/ml streptomycin 
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2 mM L- glutamine 
2% BSA 
10 mg/ml hyaluronidase (100 
U/ml) 
33 µg/ml collagenase (300 U/ml) 
10 µg/mL insulin 
0,5 µg/mL hydrocortisone 
100 ng/ml cholera toxin 
10 PBS (Phosphate Buffer Saline) 8,5 mM Na2HPO4 
2 mM KH2PO4 NaCl 
150 mM NaCl 
pH 7,4 
11 PCR-Buffer + dNTPs 100 mM Tris-HCl 
500 mM KCl 
10 mM MgCl2 
1mM nucleotids 
12 TE-Puffer 10 mM TRIS-HCl 
1 mM EDTA 
pH 7,4 
 
2.1.4. Cell lines 
Identity of used cell lines was regularly controlled by the ATCC recommended DNA 
fingerprinting.  
 Cell line Description 
1 C3H10T 1/2 Mouse embryonic fibroblasts 
2 hTERT-HME1 Non-tumorigenic breast epithelial cell line 
3 hTERT-HME1 BRAF hTERT-HME1 cell line carrying mutation in BRAF 
gene 
4 hTERT-HME1 EFGR hTERT-HME1 cell line over-expressing EGFR 
receptor 
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5 hTERT-HME1 
PI3KCA ex. 20 
hTERT-HME1 cell line carrying mutation in exon 
20 of PI3KCA gene 
6 hTERT-HME1 
shPTEN 
hTERT-HME1 cell line expressing reduced levels 
of PTEN 
7 hTERT fibroblasts Immortalized human fibroblasts 
8 MCF10A Non-tumorigenic breast epithelial cell line 
9 MCF7 Breast cancer cell line- metastatic pleural effusion 
cells 
10 MDA-MB-231 Breast cancer cell line- metastatic pleural effusion 
cells 
11 MDA-MB-231 1833 Breast cancer cell line- metastatic pleural effusion 
cells 
12 SK-BR-3 Luminal breast cancer cell line 
13 HEK-293T  Human embryonic kidney cell line 
   
2.1.5. Devices 
 
 Device Company 
1 Axio Imager Z1 Fluorescence 
microscope 
Zeiss, Göttingen 
2 Balance Kern, Balingen 
3 BenchMark Ultra Ventana, USA 
4 Capillary holder for micromanipulation Eppendorf, Hamburg 
5 Cell culture incubator Heraeus, Hanau 
6 Cell culture incubator Heraeus, Hanau 
7 Cell culture laminar flow Heraeus, Hanau 
8 Centrifuge Heraeus, Hanau 
9 Centrifuge Eppendorf, Hamburg 
10 Centrifuge, tabletop Grant Bio, USA 
11 Centrifuge, tabletop Eppendorf, Hamburg 
12 Cytospine Centrifuge Hettich, USA 
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13 DM RXA Fluorescence microscope Leica, USA 
14 Cauterizer Fine Science Tools, 
Hedelberg 
15 FACS Canto II BD Biosciences, USA 
16 Electrophoresis gel chamber Biostep, Jahnsdorf 
17 Photometer, GeneQuant II Pharmacia Biotech, 
USA 
18 Laser micro-dissection microscope P.A.L.M, Bernried 
19 LSR II flow cytometer BD Bioscience, USA 
20 Magnetic stirrer VELP Scientifica 
20 MJ Research Peltier Thermal Cycler 
PTC-200 
Bio-Rad, USA 
21 MJ Research Peltier Thermal Cycler 
Tetrad 
Bio-Rad, USA 
22 Multipipette Stream Eppendorf, Hamburg 
23 Neubauer- Cell counter Schubert und Weiß, 
Munich 
24 Optical microscope Optech, Canada 
25 Pipette controller Brand, Wertheim 
26 pH-meter Eutech Instruments, 
The Netherlands 
27 Pipettes (2 µL, 20 µL, 200 µL, 1000 µL) Eppendorf, Hamburg 
28 Power Supply for gel chamber 
electrophoresis 
MRC, Israel 
29 Pump KNF, Freiburg 
30 StuartTM Scientific roller mixer Stuart Scientific, UK 
31 Thermo mixer Eppendorf, Hamburg 
32 UV illuminator Intas, Göttingen 
33 Vortex mixers VELP Scientifica, Italy 
34 Water bath Memmert, Schwabach 
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2.1.6. Software 
 
Software Company 
AxioVision 4.5 Zeiss, Göttingen 
FACS Diva 6.1.1 BD Biosciences, USA 
FlowJo 8.8.6 TreeStar, Inc.USA 
NEBcutter V2.0 New England Biolabs, USA 
Vector NTI Invitrogen, USA 
GraphPad Prism Graph Pad software, USA 
http://faculty.vassar.edu/lowry/VassarStats.html  Website for statistical 
computation 
 
2.1.7. Primers used for the PCR amplification 
 
Gene of 
interest 
 Oligonucleotide sequence 
β-Actin Forward 5'-GTG ACA GCA TTG CTT CTG TG-3' 
 Reverse 5'-TCT CAA GTC AGT GTA CAG GC-3' 
   
EF1-α Forward 5'-CCA GTT ATG TGG CAA GAC GTT-3' 
` Reverse 5'-TCT GGG GAG AAT GGG TAG C-3' 
   
GAPDH Forward 5'- AAT CCC ATC ACC ATC TTC CAG-3' 
 Reverse 5' GCC ATC ACG CCA CAG TTT CC -3' 
   
IL6 Forward 5'- GAG AAG GCT GAG ATA AAA GGA GA -3' 
 Reverse 5'- CAT GAT ATA GAC GTT GTG GCT G -3' 
   
IL6R Forward 5'- GCG ACA AGC CTC CCA GGT TC -3' 
 Reverse 5'-GTG CCA CCC AGC CAG CTA TC -3' 
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m-dio Forward 5'-GCT CCT TAC AGT GAC TGC AG-3' 
 Reverse 5'-TCA ATG GTC ATA TTG CAG CC-3' 
   
m-IVL Forward 5'-GAA GCA GGT AGG TGT GCA G-3' 
 Reverse 5'-GCC CTA CTC AAC CTG AGA G-3' 
   
P53 exon 
2/3 
Forward 5'-AGG ACC TGA TTT CCT TAC TGC-3' 
 Reverse 5'-GAG GTC CCA AGA CTT AGT AC-3' 
   
Pseudo 
CK 19 
Forward 5'-GAA GAT CCG CGA CTG GTA C-3' 
 Reverse 5'-TTC ATG CTC AGC TGT GAC TG-3' 
   
CFL15CT
24 
 5'-CCCCCCCCCCCCCCCGTCTAGATTTTTTTTTTTTTTTTTTTTTTTTVN -3' 
CFL15C
N8 
 5'-CCCCCCCCCCCCCCCGTCTAGANNNNNNNN-3' 
CP2  5'-TCAGAATTCATGCCCCCCCCCCCCCCC-3' 
CP2-BGL  5'-TCAGAATTCATGCCGCCCCCCCGGCCC-3' 
Lib1  5'-AGTGGGATTCCTGCTGTCAGT-3' 
ddMse11  5'-TAACTGACAGddC-3' 
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2.2. Methods 
 
2.2.1. Methods for in vitro cell propagation and characterization 
 
The list of used cell lines is shown in the chapter 2.1.4.  The identity of the used cell 
lines was controlled on a regularly basis by ATCC recommended DNA fingerprinting.  
2.2.1.1. In vitro cell line propagation under conventional 2D 
conditions 
 
Cell lines were preserved in liquid nitrogen in appropriate medium containing 5% 
DMSO. Cell lines were propagated until 70% confluence apart from the cases when 
the experimental strategy did not imply differently. Cell lines were de-attached using 
Trypsin/EDTA and re-plated in an appropriate cell density. The medium was changed 
following the recommendation of the ATCC. 
2.2.1.2. In vitro cell line propagation under anchorage independent 
(3D) condition 
 
The aim of 3D cell propagation system is to enrich mammary stem and progenitor 
cell populations.  
Mammary cell lines were propagated in 2D condition until the cells reached the 70% 
confluence. Propagated cells were de-attached and washed in PBS at least two 
times. The washing steps were introduced to remove traces of serum used in the 2D 
cell line propagation culture strategy. Cell lines were propagated in ultra -low 
attachment plates in cell culture incubator at 37 °C, 5% CO2. The cell lines were 
propagated at a seeding density of 10 000 cells/ml. 
Mammosphere forming ability was assessed 7 days post-plating. During this 
period, medium was not changed. All cell lines were propagated in the same 
mammosphere medium, as listed in the chapter 2.1.2.  
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2.2.1.2.1. Preparation of poly-HEMA plates 
 
The mammary stem and progenitor cells are able to survive anchorage independent 
conditions while more differentiated progenies are undergoing anoikis. Cells are not 
able to anchorage to the dish bottom if the dishes are covered by poly-HEMA, an 
organic substance soluble in ethanol. Poly-HEMA ethanol suspension was applied to 
the culture dishes 24 h before the cells are plated. On the next day, a fine layer of 
poly-HEMA covers the culture dish and prevents the cells to adhere. Poly-HEMA (2,4 
g) was dissolved in 95% ethanol (20 ml) at 65 ⁰C. Eight hours later ethanol dissolved 
poly-HEMA was diluted 10x in 95% ethanol and added to the cell culture dishes at 
the final concentration of 12 mg/ml. Poly-HEMA coated plates were sterilized by the 
UV light in prior to cell seeding. The ethanol traces were removed by washing with 
PBS.  
2.2.1.3. In vitro differentiation of mammary cells  
 
Cell lines propagated in 3D conditions or the secondary mammospheres obtained 
from the donor’s tissue specimens were used for the in vitro differentiation in 
Matrigel©. Matrigel© is a gelatinous protein mixture secreted by Engelbreth-Holm-
Swarm mouse sarcoma cells. This mixture resembles the complex extracellular 
environment found in many tissues. Different differentiation strategies were tested 
and as a results Matrigel© “sandwich” strategy was adopted as the most efficient.  
Cells were propagated in Ham’s F-12 medium supplemented with 5% FBS, 5 μg/ml 
insulin, 1μg/ml hydrocortisone, 10 μg/ml cholera toxin, 10 ng/ml EGF, and 1× 
Pen/Strep Mix. 
Briefly, Matrigel© was diluted 1:1 with differentiation media and placed in a 
differentiation dish for 15 minutes at 37 ⁰C. On the top of the stiff gel, the mammary 
stem and progenitor cells were placed in an incubator at 37 ⁰C for 30 minutes. The 
cells were covered with an additional Matrigel© layer and left for additional 15 minutes 
at 37 ⁰C. Differentiation medium was added at the end of the embedding procedure. 
Differentiation medium was changed regularly each fourth day. 
Cells propagated in Matrigel© were examined 3-4 weeks post embedding for the 
development of the complex duct and acinar structures. 
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2.2.2.  In vitro cell propagation of the donor’s tissue specimens  
 
2.2.2.1. Tissue collective 
 
Mammary tissues were obtained from women undergoing mammary reduction 
surgeries at Caritas-Krankenhaus St. Josef, Regensburg in collaboration with Dr. 
Claus Lattrich and Dr. Norbert Heine. Mammary tissues were examined by 
pathologists at Institut für Pathologie, Universitätsklinikum Regensburg, Regensburg. 
The tissues showing the signs of breast cancer were excluded from the study and not 
used for this work (Figure 1).  
Eighty seven healthy mammary tissues were received in the period 2007-2012. 
The median age of the cohort was 27. Due to hormone changes during menopause 
and proposed hormonal influence in mammary stem and progenitor cells, tissue were 
selected based on an arbitrary age limit (45 years). However, the samples received 
from the donors older than 45 were used for the modifications of the mammosphere 
protocol presented in result section.  
 
Figure 1. The overview of the mammary tissues received in the period 2007-2012.  
2.2.2.2. Mammary tissue digestion and cell isolation 
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Mammary tissue was minced and dissociated in Ham’s F12/Dulbecco’s modified 
Eagle’s medium [F12:DMEM; 1:1 (v:v)] supplemented with 10 mM HEPES, 2% 
bovine serum albumin (BSA; Fraction V), 5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 
10 ng/ml cholera toxin, 300 U/ml collagenase and 100 U/ml hyaluronidase at 37°C for 
18 h (Figure 2).  
 
Figure 2. Digestion of the tissue specimen and cell isolation.  
At the next day, the digested cell suspension was centrifuged at 210 g for 2 
minutes at room temperature. Supernatant from the first centrifugation step contained 
single mammary epithelial and stromal cells (fibroblasts), while in the pellet were 
undigested tissue pieces, known as organoids. Single epithelial cells were subjected 
to an additional centrifugation step (290 g; 2 minutes; room temperature) and the 
epithelial cells found in pellet were re-suspended in the basal medium, washed and 
propagated in mammosphere medium in ultra low attachment plates. Mammary 
gland fibroblasts were obtained by centrifugation of the supernatant (500 g; 5 
minutes; room temperature). Fibroblasts were propagated in standard tissue culture 
flasks in DMEM medium supplemented by 10% fetal bovine serum (FBS). 
The organoids obtained in the first centrifugation step were either processed 
immediately for single cell isolation or preserved by freezing (-80 ⁰C) in organoid 
freezing medium (DMEM supplemented with 10% DMSO and 20% FCS).  
If obtained number of epithelial cells was not sufficient, organoids would be 
processed immediately by further digestion steps in DMEM/F12 supplemented with 5 
U/ml dispase and 0,25% trypsin. Trypsin was inactivated by trypsin inactivation 
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solution (TNS) or medium supplemented with serum. Digested organoids were 
centrifuged (300 g; 3 min at RT) and the epithelial cells found in the pellet were re-
suspended in mammosphere medium. 
2.2.2.3. Mammosphere protocol 
 
Single cells obtained from digested tissues were plated in ultra-low attachment plates 
at a density of 20,000 cells/ml. The number of plated cells was later modified 
according to the results shown in the chapter 3.2.3.  
Cells were grown in a serum-free mammary epithelial growth medium (MEBM) 
supplemented with B27, 20 ng/ml EGF and 20 ng/ml bFGF and 4 μg/ml heparin. 
Mammospheres were collected by gentle centrifugation (100 g) after 7 days and 
dissociated enzymatically (10 min in 0.05% trypsin, 0.53 mM EDTA-4Na). 
The obtained secondary mammosphere were used for the most of the downstream 
assays elaborated in this work (Figure 2). 
 
 
Figure 3. Mammosphere propagation. 
  
2.2.3. In vivo human mammary stem and progenitor cells differentiation 
 
In vivo experiments were undertaken in the animal facility of the University Hospital 
Regensburg. All the experiments considering NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice were done in accordance with animal application 54-2532.1-15/09 Government 
of Oberpfalz (54-2532.1-15/09; Antrag auf Genehmigung eines Versuchsvorhabens 
mit Wirbeltieren; Riegirung der Oberpfalz). 
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2.2.3.1. In vivo human mammary stem and progenitor cells 
differentiation 
 
In vivo differentiation of the human mammary stem and progenitor cells was based 
on published protocols (Liu et al., 2006; Proia and Kuperwasser, 2006). Briefly, the 
experimental strategy consists of the two surgical steps undertaken at week 3 and 
week 5 of the mouse post-natal (Figure 3). During the first surgical step the 4th 
mammary glands of 3-4 weeks old NSG mice were pre-cleared of endogenous 
mammary epithelial tissue and humanized. Mouse mammary gland humanization 
was undertaken by injecting human immortalized fibroblasts in mammary fat -pad. 
Two weeks after the first surgical step the mixture of human secondary 
mammospheres and fibroblasts of the matched tissue specimen were inoculated into 
humanized fat-pad. Mice were analyzed 8 weeks post cell inoculation. 
 
 
Figure 4. In vivo differentiation of the human mammary stem and progenitor cells in NSG mice. 
(A) The mammary fat-pad of the 3 weeks old females were cleared of endogenous mouse epithelia 
and humanized by the injection of the human immortalized fibroblasts; (B) Two weeks later, human 
mammary stem and progenitor cells co-mixed with the fibroblasts of the matched tissue sample were 
injected into humanized fat-pad; (C) Dissection and analysis of the engraftment and differentiation of 
the human mammary stem and progenitor cells in NSG mice. 
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2.2.3.1.1. Preparation of human immortalized fibroblasts used 
for xenotransplantation procedure and injection of human 
mammary stem and progenitor cells 
 
Human, h-TERT immortalized, fibroblasts were a kind gift of Professor Dr. Robert A. 
Weinberg (MIT Ludwig Center for Molecular Oncology, USA). Fibroblasts were 
propagated in DMEM media supplemented with 10% FCS and L-glutamine. The cells 
were passaged 3 times per week taking into account that cell growth confluence of 
100% should not be reached.  
Before the injection of h-TERT immortalized fibroblasts was undertaken, 
fibroblasts were de-attached and counted. Humanization of the mouse mammary fat-
pad was performed by inoculation of a half of million cells in a pre-cleared mammary 
fat pad. Of these, 250 000 cells were washed, irradiated (4 Gy) and subsequently 
mixed with 250 000 non-irradiated cell. Fibroblasts were injected into a pre-cleared 
4th mouse mammary fat-pad ensuring the point of injection is not too deep and thus 
does not pressure any leakage. Formation of a bubble in the mammary fat pad was 
taken as a proof of a suitable inoculation. 
Two weeks after humanization, 200 000 cells obtained from the propagation of 
the secondary mammospheres and 500 000 fibroblasts of the same tissue 
specimens were co-mixed 1:1 (v/v) with Matrigel© and injected into the humanized 
fat-pad of NSG mouse. Eight weeks post inoculation mouse mammary fat-pad was 
analyzed. 
2.2.3.1.2. Preparation of C3H10T1/2 fibroblasts for orthotopic 
xenotransplantation 
 
C3H10T1/2 mouse immortalized fibroblasts are derived from mouse embryonic 
fibroblasts obtained from C3H mouse strain. Fibroblasts were kind gift of Dr. John 
Stingl (Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, 
Cambridge, UK). Fibroblasts were propagated in DMEM media supplemented with 
5% FCS and L-glutamine as previously described (Eirew et al., 2008). On the surgery 
day, 225 000 fibroblasts were detached, washed and irradiated by 15 Gy. Irradiated 
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fibroblasts and 200 000 mammosphere cells were commixed, centrifuged at 500 g for 
5 min and re-suspended in 40 µl of 1:1 mixture of differentiation medium and 
Matrigel©. Cells were kept on ice until the surgery. 
2.2.3.2. Orthotopic xenotransplantation 
 
Three to four weeks old NSG female mice were used as recipient animals for the in 
vivo differentiation experiments. The limiting factors for the recipient selection were 
the weight (8 - 12 g) and age (3 - 4 weeks old). Despite the challenges working with 
pre-pubertal mice due to their size, the utilization of older mice was omitted due to 
the risk of incomplete clearance of the endogenous mammary epithelia. On the other 
hand, the radical surgical steps were lethal for the mice younger than 3 weeks or 
lighter than 8 g.  
Two different types of anesthetic solutions were compared.  
The composition of the first anesthetic solution: 
Volume 
Drug 
(concentration) 
Active substance  Dose  
0.5 ml 
Ketavet  
(100 mg/ml) 
Phecyclidine/ketamine 200 mg/kg 
0.25 ml 
Rompun  
(20 mg/ml) 
Xylazine 10 mg/kg 
5 ml PBS   
13 ml  
 
The amount of the injected anesthetic solution depended on the mouse weight. In 
general, the recommended dosage of the prepared solution is 10 µl/g. However, the 
administration of the described anesthetic solution caused the death of 20% of used 
mice. Because of this drawback alternative anesthetic solution was tested and later 
on used in experimental procedure. 
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The composition of the second anesthetic solution: 
Volume Drug (concentration) Active substance Dose 
10 ml Dormicum (1mg/ml) Midazolam 5 mg/kg 
2 ml Fentanyl (0,05mg/ml)  0,05 mg/kg 
1 ml Domitor (1mg/ml) Medetomidin 0,5 mg/kg 
13 ml  
 
The amount of the injected anesthetic depended on the mouse weight. In general, 
100 µl of the solution was administrated intra-peritoneally to mice weighting 8-12 g. 
The anesthetized animals were awakened by the administration of the 50 µl of the 
antagonist solution:  
Volume Drug (concentration) Active substance Doses  
5 ml Anexate (0,1mg/ml) Flumazenil 0,5 mg/kg 
0,5 ml Antisedan (5 mg/ml) Atipamezol  2,5 mg/kg 
3 ml Narcanti (0,4 mg/ml) Naloxon 1,2 mg/kg 
8,5 ml  
 
Mice were anesthetized by intra-peritoneal injection of described solutions and 
closely monitored during the sleep due to the possible complications. Once the 
mouse was anesthetized, the fur around the incision area was shaved and sterilized 
in order to prevent the recipient mouse of any post surgical infection. The body 
temperature was adjusted to prevent possible hypothermia. The skin of anesthetized 
mouse was then cut in a half "Y" intersection. With gentle moves the fourth mammary 
gland was released of peritoneum. Large vessels in the area of surgery were 
destroyed with an electric cauterizer to prevent accidental injury of the blood vessels. 
The cell mixture was injected into clean adipose tissue of the recipient mouse in a 
volume not higher than 40 µl. Finally, the wound was sued and mice were awakened 
by intra- peritoneal administration of “antagonist” solution.  
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2.2.3.3. In vivo breast cancer mouse model 
 
MDA-MB-231-GFP (231-GFP cells line) and MDA-MB-231 1833-GFP (1833-GFP) 
cell lines were used either to (i) address the role of the IL6 signaling in the breast 
cancer and (ii) establish the in vivo mammary stem and progenitor cell differentiation 
protocol. The cell lines were propagated by already described strategies in chapter 
2.2.2.1 and 2.2.2.2. The cell lines were injected into a pre-cleared mammary fat-pad 
of NSG mice. The first palpable tumors in either cancer cell lines, 231-GFP and 
1833-GFP, formed 20 days post inoculation. Mice were analyzed and dissected when 
the size of the primary tumor reached 10 mm in the diameter. 
2.2.3.4. Mice dissection 
 
Mice were sacrificed by cervical dislocation. The organs of interest were either 
embedded in paraffin or snap frozen (-80 ⁰C). The following organs were preserved 
for the later immunohistochemical analysis: 1) mammary glands, 2) tumors, 3) lungs, 
4) liver and 5) spleen. The bone marrow was prepared by the protocol described in 
the chapter 2.2.3.4.2  
2.2.3.4.1. Paraffin embedding of mice tissue samples 
 
The dissected tissue samples were fixed in a 4% paraformaldehyde (PFA) solution 
for 12 h. Following fixation, the samples were washed 3 times in PBS. The major 
obstacle during the tissue sectioning represents residual water in the embedded 
tissue. Therefore, dehydration of the paraffin embedded samples was achieved by 
series of washing steps in alcohol (70%, 85% and 100% ethanol, each step 1 hour). 
Then the fixed and dehydrated tissue was washed twice for 30 min in 100% xylene. 
This step serves not only the removal of alcohol from the tissue, but also facilitates 
the penetration of the paraffin during the subsequent embedding. After three 
incubation steps with paraffin (parablast embedding media), tissues were embedded. 
Paraffin embedded tissue is stored at room temperature.  
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2.2.3.4.2. Preparation of the bone marrow 
 
Tibiae and femora of experimental mice were unconstrained of skin and muscles. 
The distal parts of the bones were cut in order to make space for 26G canula to enter 
and flush the bone marrow. The bone marrow was flushed by PBS and washed with 
up to 10 ml Hank's salt solution. Next, bone marrow was centrifuged at 170 g for 10 
min to remove impurities such as fat, muscles cells and platelets. Supernatants were 
removed and the cells were re-suspended in 7 ml of PBS. Re-suspended cells were 
subjected to the gradient centrifugation (65% percoll solution). The aim of the 
gradient centrifugation was to enrich bone marrow cell suspension for the 
mononuclear cells. 
Cell suspension was carefully layered on top of the 7 ml 65% percoll solution and 
centrifuged (10 min, 1000 g).  Mononuclear cells in the density gradient remain in the 
inter-phase. Inter-phase was cleaned of percoll by PBS and then subjected to 
centrifugation at 500 g for 10 min. Precipitated cells were re- suspended in 2 ml of 
PBS. Cells were counted and placed on adhesion slides (250 000 cells per field). 
Adhesion slides were dried overnight and then stored at -20 °C. 
2.2.3.4.3. Paraffin tissue sectioning, H&E staining and micro-
dissection 
  
Hematoxylin and eosin (H&E) staining was performed in paraffin embedded samples 
Paraffin blocks containing embedded tissue were sectioned in a 5 µm thick slices 
using a microtome. Slides used for laser micro-dissection contained polyethylene 
membrane (1, 35 µm) while slides used for immunohistochemical staining were 
conventional glass slides. After sectioning slides were dried in the oven for 45 min at 
65 ⁰C. Paraffin sections were then de-paraffinized twice for 10 min in 100% xylene 
and subsequent series of ethanol steps were applied (2 min 100%, 90%, 70% 
ethanol), samples were then rehydrated with bi-distilled water and ready for staining. 
 Hematoxylin staining was performed by applying Mayer's hematoxylin (0.1%) for 2-3 
min while the staining of the cytoplasm was carried out with acidified eosin (0.1%) for 
2 min. The slides were washed in ethanol (1 min in 70%, 90% and 100% ethanol) 
and later in xylene (10 min, 100% xylene). At the end of the procedure, slides were 
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mounted with Eukitt and preserved at room temperature. Slides used for the laser 
micro-dissection were not stained with eosin because the samples were later used 
for the primary PCR strategy. Eosin shows inhibitory effect on the primary PCR.  
Examination of stained material was carried out by Dr. med. Fabian Eder from 
Institute for Pathology, University Hospital Regensburg, Regensburg.  
2.2.4. Generation of GFP labeled cells lines by lentiviral vector-mediated 
gene transfer 
 
Cancer cells lines expressing green fluorescent protein (GFP) were established for 
the purpose of the easier detection of the disseminated cancer cells in distant 
organs.  
Lentiviral gene transfer is an efficient methodology for the establishment of the 
genetically modified organisms. Lentivirus containing GFP were constructed and later 
target cell lines over-expressing GFP were established. 
2.2.4.1. Construction of the lentiviral particles- Transfection of the 
HEK-293T cells 
 
HEK-293T cells (293T cells) are derived from the human embryonic kidney. The 
293T cells are frequently used as lentiviral producer cells due to their high 
transfection ability.  
The 293T cells were propagated in DMEM media supplemented with 10% FCS and l-
glutamine. The transfection ability of the 293T cells depends on the culture 
conditions. Therefore, cells were never allowed to reach 100% confluence before the 
transfection. Ten million cells were seeded in a 10 cm cell culture dishes 15h before 
the transfection. Transfection was performed once the cells reached 70% confluence. 
Transfection medium (DMEM; 10% FCS) containing 25 µM chloroquine was added 
45 min before the start of transfection. Chloroquine’s function is to block plasmids 
degradation in the endosome/lysosome system which increases transfection rate 
(Ciftci and Levy, 2001; Erbacher et al., 1996). Half an hour to two hours after 
chloroquine addition the medium was replaced by transfection mixture.  
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The composition of the transfection mixture was:  
5 µg pMD2G (envelope plasmid),  
20 µg psPAX2 (packaging plasmid),  
20 µg lentiviral plasmid (containing the target genes), 
add water up to 250 µl, 
add 250 µl of  0.25 M CaCl2 solution.  
This mixture was diluted into 2x HEBS buffer. The transfection mixture was added 
drop wise to HEK-293T cells. The medium was replaced 6h after the transfection 
mixture was added. The addition of the transfection mixture is taken as the start point 
of the S2 work. Therefore, all work was performed according to the safety 
recommendation prescribed for the S2 work. The lentiviral particles containing GFP 
were collected 48h and 72h post transfection. Lentiviral particles were stored at -
80⁰C.  
2.2.4.2. Determination of virus titer 
 
Virus titer represents the number of the virus particles in 1 ml. Determination of the 
virus titer was performed using 231-GFP or 1833-GFP cell lines. Cells were 
propagated in a 12-well plate. The cells (4 x 104 cells/well) were plated and 
propagated overnight at 37 °C. On the next day, medium was removed, cells were 
washed and virus diluted in 1:10, 1:100, 1:1000, 1:10000 as well as undiluted virus 
were added to the cells. GFP fluorescent cells were noticeable 24h post infection.  
Titer of the produced virus was determined by measuring the number of the GFP 
positive cells in a given population by the following equation: 
Titer = percent of GFP-positive cells * number of seeded cells / infection volume 
2.2.4.3. The selective propagation of the transduced cells 
 
Lentiviral vector used for the stabile integration and expression of the GFP contain a 
gene for the puromycin resistance. Therefore, transduced cell have stabile integrated 
and expressed gene for puromycin resistance. Treatment o f transduced cell with 
puromycin depletes uninfected cells. To determine puromycin concentration, 50 000 
2. Materials and Methods 
 
42 
 
non-transduced target cells were seeded in a 24-well plate. Day after seeding the 
growth media was supplemented with in grading puromycin concentration ranging 
from 0-20 µg/ml. The cells were propagated 4 days and the optimal concentration 
required for the selection of transduced cell population was determined as a minimal 
concentration in which 100% of un-transduced cells are dead after 4 days. 
2.2.5. Gene specific PCR 
 
The assessment of the transcription of gene of interest, verification of the epithelial 
origin of the in vivo engrafted epithelial structures and assessment of the cDNA 
libraries was performed by PCR.  
 
PCR reaction was prepared following Table 8. 
Volume Reagent 
7,15 µl Ultra pure DEPC- water 
1 µl PCR buffer + dNTP 
0,5 µl 
Forward oligonucleotide (8 µM 
concentration) 
0,5 µl 
Reverse oligonucleotide (8 µM 
concentration) 
0,25 µl BSA 
0,1 µl Taq DNA-polymerase 
0,5 µl DNA 
 
Table 8. PCR reaction mixture. 
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The standard program for gene specific PCR is listed in Table 9. 
 Temperature Time 
1. 94 ⁰C 2:00 min 
2. 58 ⁰C 0:30 min 
3. 72 ⁰C 2:00 min 
4. 94 ⁰C 0:15 min 
5. 58 ⁰C 0:30 min 
6. 72 ⁰C 0:20 min 
7. Repeat steps from step 4 to 6 (14 times) 
8. 94 ⁰C 0:15 min 
9. 58 ⁰C 0:30 min 
10. 72 ⁰C 0:20 min 
11. Repeat steps from step 8 to 10 (24 times) 
12. 72 ⁰C 2:00 min 
13. 4 ⁰C ∞ 
 
Table 9. Program used for the PCR reaction. 
Result of PCR was visualized with agarose gel electrophoresis using ethidium-
bromide.  
2.2.5.1. Agarose gel electrophoresis 
 
Amplified products of the specific PCR were separated with gel electrophoresis,1.5% 
agarose concentration in TBE buffer with addition of ethidium-bromide (0,5 µg/ml). 
Samples were mixed with a loading dye and loaded in the gel. PCR amplicons were 
separated at 160 V for 45 min. 
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2.2.5.2. Total mRNA reverse transcription and cDNA amplification 
from single or few cells 
 
Total mRNA reverse transcription and cDNA amplification from single or few cells 
was performed as described elsewhere (Hartmann and Klein, 2006). 
2.2.6. Unspecific labeling of cell membrane- PKH26 staining 
 
The unspecific labeling of the cellular membrane by PKH26 dye was used for the 
detection and isolation of the single mammary stem and progenitor cells.  
PKH26 dye labels phospholipids in the cell membrane. During each cell division 
membrane is divided between daughter cells. Therefore, f luorescent dye is diluted by 
half after each cell division. Optimal dye concentration depends on proliferative rate 
of cell type; if a cell is over-saturated by PKH26 daughter cells despite the cell 
divisions would be fluorescent. Therefore, determination of the optimal concentration 
is a crucial step in the protocol. Staining of the 107 cells at final concentrations of 2 X 
10-6 M PKH26 dye was performed by the following protocol: 
Cells were washed using medium without serum and then centrifuged at 400 g for 5 
min. Pellet was re-suspend in 1 ml of diluent C by pipetting to ensure complete 
dispersion. Prior to staining, 4 X 10-7 M PKH26 dye was prepared using diluent C. 
Cells were added rapidly to 1 ml of dye and mixed. Rapid and homogeneous mixing 
is a critical point for the uniform labeling. Cells were incubated at 25 °C for 5 min. 
Staining reaction was stopped by adding an equal volume of serum or compatible 
protein solution (i.e., 1% BSA). Cells were washed with an equal volume of serum-
free medium or PBS and centrifuged at 400 g for 10 min at 25 °C to remove cells 
from staining solution. Centrifugation step was repeated at least 3 times in order to 
clean cells of ethanol traces and diluent C. Cells were examined using fluorescence 
microscopy. Staining should be uniform and is typically 100 - 1 000 times brighter 
than background auto-fluorescence. 
2.2.7. Quantification of Interleukin 6 and soluble Interleukin 6 receptor  
 
Interleukin 6 (IL6) and soluble Interleukin 6 receptor (sIL6R) expression were 
quantified in growth media of used cell lines or media of patient tissue culture. 
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Measurements of human IL6 production was performed by “Human IL-6 DuoSet” 
elisa kit following manufactures protocol (R&D Systems).  
Human sIL6R production was measured by “Human sIL-6R alpha DuoSet” elisa kit 
following manufactures protocol (R&D Systems). 
Briefly, after cells were propagated under experimentally required conditions 
growth media was collected and 100 µl of supernatant were applied on 96-well plates 
prepare by provided manufacturer protocols. Final results were obtained by using 
micro-plate reader set at 450 nm. Positive and negative controls were used. 
Moreover, for both proteins 7 points standard curves were used for obtaining the final 
results.  
2.2.8. Flow cytometry 
 
The analysis of membrane-bound IL6R was performed in collaboration with Dr. 
Melanie Werner-Klein. The expression of membrane bound IL6R was assessed by 
flow cytometry by using LSR II flow cytometer (BD Biosciences). Briefly, cells 
propagated under anchorage independent conditions or under standard conditions 
were blocked with 10% AB-serum and incubated with anti-IL6R antibodies. Obtained 
results were analyzed with FACS Diva 6.1.1 and FlowJo 8.6.6 software.  
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3. Results 
3.1. Overview of the research rationale 
 
To study the effect of IL6 signaling in mammary gland several aspects had to be 
addressed. First, novel approaches and methodological strategies had to be 
developed, while some of the published methods had to be adapted. These issues 
are elaborated in the chapter 2 of the Result Section. 
Once the modified approaches and novel methods were developed, the mechanism 
and phenotypic consequences of the IL6 signaling in mammary cells had to be 
identified. The obtained results indicated a role of IL6 signaling in normal mammary 
stem and progenitor what enabled me to address the impact of IL6 signaling in 
cancer stem cells (Figure 1).   
 
Figure 1. The rationale of the PhD work. 
3.2. Development and modification of the protocols used for the study of IL6 
signaling influence in the mammary gland  
The work on normal adult mammary stem and progenitor cells is challenging due to: 
1) the low absolute and relative number of adult mammary stem cells; 2) difficulties in 
maintaining and propagating adult stem and progenitor cells for longer time period in 
vitro and 3) technical obstacles, such as low efficiency of protocols used for isolation 
3. Results 
 
47 
 
and propagation of adult mammary stem and progenitor cells in vitro and low 
efficiency of protocol used for in vivo mammosphere differentiation in 
immunodeficient mice.  
Isolation of mammary stem and progenitor cells is highly relevant because it 
determines the number of cells which can be used for the downstream assays. 
Therefore, the first aim was to increase the efficiency of the mammary stem and 
progenitor cell isolation and propagation. 
 
3.2.1. Improvement of the cell isolation protocol 
 
The aim of the mammosphere assay is propagation of normal human mammary stem 
and progenitor cells. Isolation of the single mammary epithelial cells was achieved by 
digestion of donor’s tissue specimens. The mammary tissues of patients undergoing 
mammary reduction-plasty were first examined by a pathologist. Samples containing 
potential cancerous lesions were excluded from downstream approaches. Tissue 
examination was performed in semi-sterile conditions resulting in contamination of 3 
out of 87 samples. Isolation of single cells from the mammary specimens was 
achieved by mechanic and enzymatic digestion, while subsequent isolation of 
epithelial cells was accomplished by differential centrifugation steps.  
 
 
Figure 2. Isolation and growth culture of the normal mammary stem and progenitor cells.  
Mammosphere protocol. Growth of enriched stem and progenitor cell population is enabled by 
propagation of cells under anchorage independent conditions. While differentiated cells are not able to 
survive anoikis, mammary stem and progenitor cells form spherical colonies, named as 
mammospheres. 
The centrifugation steps of the cell isolation protocol were identified as import 
determinants of overall efficiency of the method. Application of lower centrifugation 
speeds in shorter time can reduce the number of obtained cells. Therefore, the 
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influence of the centrifugation time and speed during cell isolation on the overall 
number of obtained secondary mammospheres was tested. Separation of epithelial 
and mesenchymal cells was achieved by 290 g centrifugation for 2 minutes at room 
temperature. To test whether higher g- forces increase epithelial cells recovery, 
centrifugation conditions were modified to 350 g for 4 minutes (Figure 3). 
 
 
Figure 3. Isolation of single cells from mammary tissue. Mammary tissue was mechanically and 
enzymatically digested. Epithelial and mesenchymal cells were isolated by application of multiple 
centrifugation steps. Modified steps are indicated by #.  
 
The second centrifugation step during cell isolation has the aim to separate epithelial 
and mesenchymal cells (Figure 3). The increased centrifugation speed and time 
resulted in an increase of number of pelleted cells (Figure 4 a). These cells were 
tested for their ability to form secondary mammospheres. It was found that increased 
centrifugation parameters resulted in increased numbers of isolated cells with the 
mammosphere forming ability (Figure 4 c). 
On the other hand, increased centrifugation parameters resulted in considerably 
less cells isolated from the supernatant (Figure 4 b). Cells found in supernatant were 
later used for in vivo mammosphere differentiation and thus the number of obtained 
cells is a relevant parameter. However, propagation of supernatant-derived cells 
resulted in slightly reduced numbers of cells after 7 days of propagation under 
anchorage dependant conditions when centrifuged at 350 g for 4 min as compared to 
290 g for 2 minutes. In vitro propagated cells obtained from both centrifugation 
conditions were reaching confluence in a short time. Therefore, decreased number of 
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isolated mesenchymal cells due to increased centrifugation conditions had no 
consequences for later experiments (Figure 4.d). Subsequently, the following step, 
the washing centrifugation step, was adjusted to the modified parameters (350 g; 4 
minutes; RT instead of 290 g; 2 minutes; RT).  
Optimization of the cell isolation protocol from mammary gland specimens resulted in 
a 2 fold increase of cultivated secondary mammospheres (Figure 4 c). 
 
Figure 4. Modification of the cell isolation protocol. Increased numbers of mammosphere forming 
cells were achieved by modification of the centrifugation parameters. (A) Increased centrifugation 
speed and time resulted in the sedimentation of higher cell numbers (p= 0.08, two- tailed unpaired t-
test); (B) Due to the higher centrifugation speed for prolonged time, the number of the cells isolated 
from the supernatant was reduced (p= 0.57, two- tailed unpaired t-test); (C) The increased number of 
the pelleted cells resulted in overall higher number of the propagated secondary mammospheres (p< 
0.0001, two- tailed unpaired t-test); (D) Reduced number of plated cells from supernatant did not 
influence fibroblast propagation (p= 0.82, two- tailed unpaired t-test). After 7 days equal numbers of 
fibroblast were counted in both conditions. Results were obtained using 3 different donor’s tissue 
specimens (n=3). Experiments were performed in technical duplicates.   
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The higher number of isolated and plated cells might cause the problem during 
the mammosphere outgrowth due to higher cells densities. Increased number of 
isolated epithelial cells raised the question about the most effective cell density for 
the mammosphere propagation. Therefore, the optimization of the mammosphere 
protocol was performed. 
3.2.2. Improvement of the  mammosphere culture protocol 
 
The numbers of plated epithelial cells isolated from mammary tissue range from 10 
000 cells/ml to 100 000 cells/ml in various published protocols. 
The aim of this experiment was therefore to define the optimal number of seeded 
cells for obtaining maximal mammosphere counts in the second and higher 
passages. Two limiting factors were considered to determine the range of cell density 
values: (1) Higher cell density may induce mammosphere fusion while (2) lower 
density can reduce paracrine cell stimulation. Therefore, 3 different cell densities 
were tested: 10 000 cells/ml, 50 000 cells/ml and 200 000 cells/ml. Mammospheres 
obtained after propagation of the cells isolated from the tissue specimen were 
counted, dissociated and further propagated in ultra-low attachment plates. Seven 
days after the first passage, mammospheres were again counted, dissociated and re-
plated. This cycling procedure was repeated up to 6 times in case of the highest 
density; while in the case of 10 000 seeded cells per ml mammospheres were 
maintained up to 4 passages (Figure 5).  
Mammospheres grown in different cell densities showed differences in the size and 
number. Mammospheres grown in 200 000 cells/ml condition were the largest in size 
and showed increased fusion level (Figure 5). As a result, the final number of 
mammosphere forming cells in this condition might be under-estimated. 
Mammospheres were found for up to 6 passages upon tissue dissociation in the 
condition 200 000 cells/ml. However, in the condition 10 000 cells/ml mammospheres 
were detected for up to 4 passages (Figure 5 a). 
In the first week, percentages of mammosphere forming cells (MFC) were similar 
for different conditions while in the second week overall percentages of MFC were 
significantly increased compared to the first week (Figure 5 b). Such an effect is 
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mainly because cells plated in the second week had been already selected for the 
anoikis survival. In later passages the percentage of MFC was rapidly decreased. 
The strongest reduction was observed in case of 10000 cells/ml propagated cells. 
 
Figure 5. Influence of the cell density on mammosphere outgrowth and propagation. (A) Cell 
density had no influence on mammosphere outgrowth. Ratios between differential seeded cell 
numbers were retained for secondary mammospheres. The highest seeding density gave possibility to 
maintain mammospheres for longer period (up to 6 passages); (B) Frequency of the mammosphere 
forming cells in population of seeded cells. The cells obtained from the secondary mammospheres 
showed the highest relative number of mammosphere forming cells (p<0.01, two- tailed unpaired t-
test). Results were confirmed using 2 additional donor’s tissue specimens (n=3). Representative 
results are shown. Experiments were performed in technical duplicates. 
If the seeding density does not influence mammosphere propagation then the 
numbers of obtained mammospheres in higher densities (50000 cells/ml and 200000 
cells/ml) would be in accordance to the number of mammospheres obtained under 
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10000 cells/ml condition multiplied by seeding factor.  
Influence of the seeding density on mammosphere propagation was measured by 
setting the numbers of mammospheres counted in the 10000 cells/ml conditions as a 
reference for mathematical prediction. The number of counted mammospheres in 
10000 cells/ml conditions was amplified 5 or 20 times to get the predicted numbers of 
secondary mammospheres in 50000 cells/ml or 200000 cells/ml conditions, 
respectively (Figure 6). Experimental and predicted data were comparable during the 
first 3 passages.   
 
Figure 6. Experimentally observed mammosphere numbers and mathematical prediction of the 
mammosphere numbers. Mathematical prediction was done by amplifying the numbers of 
mammospheres obtained at 10 000 cells/ml 5 or 20 times for seeding densities 50 000 cell/ml or 200 
000 cells/ml, respectively. Comparison showed no influence of a seeding number on mammosphere 
outgrowth and propagation. Experiment was performed with 3 different tissue specimens confirming 
presented results (n=3). Each experiment was performed in technical duplicates. 
Altogether, outgrowth and propagation of epithelial cells isolated from mammary 
tissue in the density of 200000 cells/ml gives the optimal conditions for outgrowth of 
sufficient number of the secondary mammospheres. 
3.2.3. Establishment of in vitro differentiation on a panel of HME cell 
lines- In vitro differentiation of the selected mammary cell lines 
 
Characteristic of stem and progenitor cells is the ability to differentiate down in 
several lineages to form all of the cell types that are found in the mature tissue. 
Thereby, in vitro differentiation is frequently used to assess differentiation ability of 
tested cells. 
The adult human mammary gland is organized in a complex network of 3D duct and 
alveolar structures. The mammosphere propagation in the 3D matrices (i.e. collagen, 
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Matrigel©) promotes development of structures similar to those of the adult human 
mammary gland. The aim of the following experiment was to compare different 
Matrigel© differentiation strategies for reaching the best conditions for differentiation 
of the secondary mammospheres. Comparison of different strategies was performed 
by testing differentiation ability of different HME cell lines (Figure 7).  
The panel of HME isogenic cell lines showed differential morphological struc tures 
upon differentiation in Matrigel© by using two different embedding approaches: “3D 
on top” assay and “sandwich” model. The differentiation ability was analyzed by the 
ability of cells to form branching and acinar structures when embedded in Matrigel©. 
Differentiation ability of cells embedded following the recommendations of “3D on 
top” assay could not be analyzed due to the cell death shortly after cells embedding.  
However, the HME cell lines showed high proliferative and differentiation abilities 
upon embedding following recommendation given for the “Sandwich” model. 
HME cell line containing BRAF mutation failed to survive in extracellular matrix. HME 
EGFR and HME wt cell lines differentiated in mass-like structures after 3-4 weeks in 
Matrigel©. Observed mass-like structures resulted from proliferation of single cells 
indicating high proliferative ability of HME EGFR cell line. HME PIK3CA cell line had 
a grape-like morphology, while HME cell line down-regulated for PTEN grown in 
branching structures similar to duct morphology of functional breast tissue (Figure 7). 
Duct morphology of HME PIK3CA cell line is similar to the ducts observed in adult 
mammary gland. 
 
Figure 7. Differentiation of HME cell lines in 3D reconstituted extracellular matrix. HME cell 
lines, containing oncogene mutation, showed different morphologies. HME wt and HME EGFR cell 
lines have mass like wile HME PIK3CA cell line have grape -like morphological differentiation pattern. 
HME shPTEN showed stellate type of differentiation. HME BRAF failed to survive in Matrigel
©
. 
“Sandwich” Matrigel
©
 embedding was applied for the in vitro differentiation.  
Experiments were repeated 3 times with cells of 3 different passages (n=3). Each experiment was 
performed in technical duplicates.  
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Altogether, modified “sandwich” embedding Matrigel© differentiation approach was 
applied for the purpose of this work. The modification of the “sandwich” model 
concerned the dilution of Matrigel©. Matrigel© was diluted in prior to use 1:1 in 
differentiation medium and in this way the overall cost of the experiment was reduced 
while the high differentiation ability of the analyzed cells was achieved.  
3.2.4. In vivo engraftment and propagation of the human mammary cells  
 
The in vivo differentiation ability of human adult stem and progenitor cells is usually 
analyzed by xenograft models which utilize immune-deficient mice, such as NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice.  
3.2.4.1. In vivo engraftment and growth of human mammospheres in 
NSG mice 
 
The most frequently used published protocol describes important steps for the 
successful engraftment and differentiation of the adult stem cells (Liu et al., 2006; 
Proia and Kuperwasser, 2006). Following this protocol I tried to transplant and 
differentiate HME wt cells in the mammary fat-pad of NSG mice. The procedure was 
performed in two surgical steps. During the first surgical step, the mouse mammary 
fat-pad of 3-4 week old NSG mice was cleaned of endogenous mammary cells and 
“humanized” with human immortalized fibroblasts (HIF). Two weeks post HIF 
injection, human mammospheres were injected into the “humanized” area. Eight to 
twenty weeks after mammospheres had been injected mice fat-pads were examined 
for the presence of human mammary cells (Figure 8).  
For the establishment of the protocol, 114 mice were used. Mammospheres of the 
HME cell line were inoculated in 80 mice while 34 mice were inoculated with human 
secondary mammospheres derived from the donor’s tissue specimens. None of the 
isolated mouse mammary fat-pads contained human cells indicating problem of 
engraftment or survival of human cells into the mammary fat-pad of NSG mice. 
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Figure 8. In vivo differentiation of the human mammospheres in NSG mice.  
(A) Three weeks old female mice were subjected to resection of endogenous mammary epithelial 
compartment. In the cleared fat cell compartment irradiated human fibroblasts were inoculated. (B) 
Humanized mammary fat-pad serves as matrix for engraftment and propagation of mammospheres. 
(C) Mouse mammary fat-pad was analyzed eight to twenty weeks post inoculation. Detailed protocol is 
in (Liu et al., 2006; Proia and Kuperwasser, 2006).  
MDA-MB-231 1833 GFP (1833 GFP) cell line was used as a positive control for the 
engraftment and propagation of human cells in immune-deficient mice. The 
expression of green fluorescent protein in (1833 GFP) was achieved by stable 
integration of GFP by using lentiviral gene transfer. In a group of 6 mice 1833-GFP 
cell line was inoculated by the already described protocol. Two weeks post 
inoculation the first signs of primary tumor formation were observed. All of 6 mice 
developed primary tumors. Due to the size of the primary tumor, mice had to be 
sacrificed 10 weeks post inoculation (Figure 9).   
 
Figure 9. The MDA-MB-231 1833 cell line forms mammary tumors in NSG mice. 1833-GFP cell 
line was inoculated in the pre-cleared mouse mammary fat pad. The fourth mouse mammary fat -pad 
was pre-cleared and endogenous mouse epithelia was removed. In the remnant fat -pad human 
immortalized fibroblasts were injected. Two weeks after fi rst surgical step 200 000 cancer cells were 
injected. Tumors were palpable 2 weeks after injection, 3 weeks later mice were dissected. Results 
were obtained from group of 6 mice (n=6).  
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Postmortem examination revealed the presence of macroscopic mammary tumors 
(~1 cm in diameter) and the presence of macroscopic lung and liver metastasis 
(Figure 10 a-f). Histo-pathological examination confirmed the mammary origin of the 
primary tumor. Macro-metastases were present in distant organs (lungs and liver) of 
all mice. Focal liver macro-metastasis were found in one of six mice (1/6; 16%) while 
lung metastasis were found in all of the experimental mice (6/6). Brain metastases 
were not detectable. Bone marrow was isolated from the tibiae and femura of the 
experimental mice. Examination of bone marrow by fluorescent microscopy showed 
up to 1,8% of GFP positive cells (Figure 10 g-i). 
 
Figure 10. The MDA-MB-231 1833-GFP cells form mammary metastatic tumors and metastasize 
in NSG mice. (A-B) MDA-MB-2311833-GFP cell line developed mammary tumors. Mice were killed 7 
weeks post cell inoculation. (C-D) Focal liver macro-metastases were confirmed by H&E staining. (E-
F) Lung metastasis and big deposits in pleural effusion were observed. (G-I) Bone marrow was 
isolated and examined for the presence of GFP positive cells. Six mice were used for this experiment 
(n=6). 
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Engraftment and growth of robust human cancer cell line in NSG mice but the 
lack of HME wt cell line engraftment and propagation indicates necessity for protocol 
improvement. The MDA-MB-2311833-GFP cell line experiment suggested that 
engraftment and survival of human cells in NSG mice might depend on the 
environmental signals provided mainly by fibroblasts used for mammary fat -pad 
humanization. Therefore, the next step was to check whether the human 
immortalized fibroblasts engraft into mammary fat-pad and do they support the 
growth and differentiation of adult mammary stem and progenitor cells.  
3.2.4.2. In vivo engraftment and growth of human mammospheres in 
NSG mice- protocol modification 
 
Human mammary glands contain as larger fibrotic compartment compared to murine 
glands and moreover, fibroblasts play an important role in the development of human 
mammary stem cells. For these differences, engraftment of human immortalized 
fibroblasts (HIF) into pre-cleared mouse mammary fat-pad is tought to be necessary 
for the subsequent engraftment and differentiation of adult human mammary stem 
and progenitor cells.  
Described failure of normal human mammary epithelia to engraft , but ability of human 
cancer cell line to engraft and propagate in NSG mice suggested that “humanization” 
of the recipients’ fat-pad failed. The failure of mammary fat-pad “humanization” may 
be due to the lack of HIF engraftment into pre-cleared mouse mammary fat-pads. 
Therefore, the fat-pads of animals where no engraftment of human epithelial cells 
could be detected were examined for the presence of HIF. 
HIF were not detectable by histological and immunohistochemical examination, while 
humanized mammary fat-pads showed similar morphology to pre-cleared but not 
humanized fat-pads (Figure 11 a-b).  
This finding suggested that the used HIF were not able to engraft and subsequently 
support development of human mammospheres in mouse mammary fat-pad.  
Therefore, mouse mammary C3H10T1/2 fibroblasts were checked for the ability to 
form a fibroblast-containing stroma in mouse mammary fat-pad. 
Interestingly, murine fibroblasts rapidly engrafted in the fat-pad and formed large 
fibroblast-containing regions (Figure 11 c).  
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Figure 11. Inoculation and propagation of fibroblasts in the mouse mammary fat-pad. (A) 
Mammary fat-pads were cleared of endogenous mouse epithelial cells; (B) Engraftment of human 
immortalized fibroblasts in cleared mouse fat-pad was not detected as indicated by *; (C) Engraftment 
of C3H10T1/2 murine fibroblasts (engraftment of C3H10T1/2 fibroblasts is indicated by #, while mouse 
endogenous mammary fat-pad stroma is tagged by *).   
Engraftment of C3H10T1/2 fibroblast into mouse mammary fat pad suggested that 
inoculation of human epithelial cells co-mixed with C3H10T1/2 fibroblasts may result 
into successful engraftment of human cells.   
Human mammary HME wt cells and HME EGFR cells were co-mixed with 
C3H10T1/2 fibroblasts and injected into pre-cleared fat-pad of NSG mice. Five to 
eight weeks post inoculation mice were examined for the outgrowth of human cells. 
HME wt and HME EGFR cells were found to have successfully engrafted in mouse 
mammary fat-pads. Their human origin was confirmed by immune-staining using an 
antibody which specifically binds to human cytokeratin 18 (Figure 12 a). 
Moreover, the analysis of mouse mammary fat-pads inoculated with HME cells 
confirmed presence of cytokeratin 5/14 expressing cells (Figure 12 c). Estrogen 
receptor expression of observed human epithelial cells could not be observed  (Figure 
12 d).  
To exclude the possibility that C3H10T1/2 fibroblasts form tumors over time, a control 
group of mice (n=4) was observed after inoculation. During 60 weeks, none of the 
mice showed any sign of illness, tumor formation or other side effects promoted by 
immortalized fibroblasts. Dissection and analysis of control mice confirmed absence 
of tumor formation by C3H10T1/2 fibroblasts. 
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Figure 12. Engraftment of HME EGFR cell line in mammary fat-pad. (A) HME EGFR cell line 
successfully engrafted and propagated in mouse mammary fat-pad; (B) Engrafted cells expressed 
human cytokeratin 18; (C) Developed structures express cytokeratin 5 and 14; (D) Expression of 
estrogen receptor could not be detected. Twenty mice were used for the purpose of the protocol 
improvement (n=20).    
 After, HME cells had successfully engrafted, human mammospheres obtained 
from the reduction mammoplasty were tested. The secondary mammospheres were 
co-mixed with C3H10T1/2 fibroblasts and transplanted into pre-cleared mammary fat-
pad of NSG mice and supplemented with estrogen pellets. Analysis of the mammary 
fat-pads 8 weeks post-inoculation showed that in case of 4 animals (67%) 
engraftment of mammospheres was successful what confirmed that uti lization of 
C3H10T1/2 fibroblasts for the engraftment of human cells into mammary fat-pad of 
NSG mice results in an improved in vivo differentiation protocol (Figure 13 b and c).  
 Development of a novel strategy for the in vivo differentiation of human mammary 
stem and progenitor cells by utilization of C3H10T1/2 murine fibroblasts enabled the 
start of study of IL6 trans-signaling influence in normal and malignant stem and 
progenitor cells. 
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Figure 13. Engraftment of human mammospheres in mouse mammary fat-pad of NSG mice and 
protocol modification. (A) Mammary fat -pads of 3 weeks old NSG mice were pre-cleared and 
inoculated with co-mixed murine C3H10T1/2 fibroblasts and mammospheres; (B) Eight weeks post-
inoculation human engrafted cells were detected. (C) Comparison of engraftment efficiency by using 
two different fibroblasts types (HIF vs. C3H10T1/2). Utilization of C3H10T1/2 fibroblasts instead of HIF 
resulted in improvement of in vivo differentiation protocol (NM = mammospheres obtained from 
propagation of normal mammary gland; normal mammospheres).  
3.3. IL6 signaling in normal mammary cells 
 
 Activation of the IL6 signaling has been implicated in regulation of important cell 
signaling pathways, such as Notch and Wnt (Ben-Porath et al., 2008; Sansone et al., 
2007). Therefore, I tried to assess the impact of IL6 signaling and how IL6 signals in 
normal mammary stem and progenitor cells. 
3.3.1. The activation of the IL6 signaling promotes survival and 
proliferation of the mammary cells under anchorage independent 
conditions 
 
Stem and progenitor cell proliferation can be assessed by cell propagation under 
anchorage independent conditions. Thus, the sphere forming ability of MCF10A and 
HME wt was analyzed upon activation or blockage of IL6 signaling. The cell lines 
were propagated under sphere conditions for 7 days in medium supplemented either 
with IL6, anti-IL6 blocking antibody or PBS. Activation of IL6 signaling promoted 
survival and propagation of HME wt and MCF10A cells under anchorage 
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independent environment. On the other hand, the number of spherical colonies was 
slightly reduced upon application of IL6 blocking antibody (Figure 14). 
 
Figure 14. IL6 increases cell survival and sphere numbers of human mammary cell lines under 
anchorage independent environment. (A) Sphere forming ability of MCF10A cell line in presence of 
IL6 or anti-IL6 (One way ANOVA p=0.009; control vs. IL6, p=0.03, two- tailed unpaired t-test); (B) 
Sphere forming ability of HME wt cells in presence of IL6 or anti-IL6 (One way ANOVA p=0.008; anti 
IL6 vs. IL6, p=0.01, two- tailed unpaired t-test). Results represent a mean of 3 experiments performed 
with cells of different passages (n=3). Each of 3 experiments was performed in technical duplicates.  
 
Taken together, these results suggest that IL6 signaling impacts on survival and 
propagation of mammary cell lines when propagated under anchorage independent 
condition. 
3.3.2.  IL6 signals in mammary cells via trans-signaling 
 
The increase of sphere forming ability by addition of IL6 signaling poses the question 
for the mode of IL6 signaling. To test whether the signal can be transmitted through 
membrane-bound IL6 receptor (IL6R), mammary cell lines were propagated under 
conventional (2D) conditions and under anchorage independent (3D) conditions, 
isolated and stained with antibodies directed against the IL6R (anti-IL6R). IL6R 
surface expression was quantified by FACS. 
FACS analysis suggested the absence of mammary cells expressing membrane- 
bound IL6R in MCF10A and HME wt cells. Moreover, cell propagation under 3D 
conditions did not result in detectable expression of membrane-bound IL6R. Of note, 
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fibroblasts isolated from the normal mammary gland and propagated for two weeks 
did not show any detectable membrane-bound IL6R expression. 
 
Figure 15. Mammary cell lines do not express membrane- bound IL6R. FACS analysis could not 
detect presence of membrane- bound IL6R on (A) MCF10A and (B) HME wt cell lines, neither on cell 
growth under 2D nor under 3D culture conditions; (C) Mammary fibroblasts do not express membrane-
bound IL6R; (D) Blood donated by a healthy donor was used as a positive control. Biotinilated anti-
IL6R antibody, UV-4 clone and mouse IgG1 κ, isotype control were used for FACS analysis. The 
experiment was performed 3 times (n=3).  
 To address how the IL6 signal is transmitted the next experiment tested whether 
IL6 trans-signaling could be utilized by mammary cells. Trans-signaling involves 
expression of the soluble form of IL6R (sIL6R). It was therefore tested whether the 
mRNA of IL6 and IL6R is expressed by individual MCF10A and HME wt cells. 
 The mRNA of the single cells grown under 2D and 3D conditions were isolated 
and reversely transcribed into cDNA (Figure 16 a). In the case of MCF10A cells, the 
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results confirmed the presence of cells grown under 2D culture conditions expressing 
IL6 and IL6R, but IL6 expression could not be detected in cells grown under 3D 
culture conditions (Figure 16 b). Moreover, the analysis of IL6 and IL6R co-
expression in MCF10A cells showed that majority of cells do not co-express IL6 and 
IL6R and thus the analysis suggested that IL6 trans-signaling could be achieved via 
paracrine stimulation where some cells express IL6 while the other express IL6R 
(Figure 16 c).  
Assessment of the IL6 and IL6R expression in HME wt cells demonstrated increase 
in numbers of cells expressing IL6 and IL6R when grown under 3D conditions (Figure 
16 d). The analysis of the IL6 and IL6R co-expression showed that majority of cells 
(87%) grown under 3D could trigger IL6 trans-signaling in autocrine way (Figure 16 
e). Interestingly, all HME wt cells when grown under 3D culture conditions could 
contribute to IL6 trans-signaling.  
 
Figure 16. Expression of IL6 and IL6R in mammary cell lines. (A) Experimental design. Total 
mRNA of single 2D grown cells or 3D spheres were isolated and reverse transcribed. Expression of 
IL6 and IL6R in (B) MCF10A was assessed by PCR; (C) co-expression of IL6 and IL6R in MCF10A 
cells; (D) HME wt cells grown under 2D or 3D conditions express IL6 and IL6R (E) HME wt co-express 
IL6 and IL6R. The transcription assessment was performed by using multiple samples.   
3. Results 
 
64 
 
3.3.3. Mammary cell lines produce and secrete IL6 and sIL6R 
 
Since the mRNA of IL6 and IL6R could be detected in MCF10A and HME cells, the 
presence of the proteins was checked as a final verification of the ability of mammary 
cells to trigger IL6 trans-signaling. For this, the media of cells grown under 2D 
conditions were collected and used for measuring the IL6 and sIL6R protein. As 
control, the levels of the IL6 and sIL6R were assessed in fresh media. 
It was found that both mammary cell lines are able to produce IL6 and sIL6R, 
indicating that trans-signaling underlines IL6 transmission in both cell lines (Figure 17 
a). On average, HME wt cells showed a ten-fold higher IL6 protein production than 
MCF10A cells.  
In addition, HME wt cells displayed a dose density- dependent secretion of IL6 and 
sIL6R, with the protein level of IL6 being inversely correlated to cell density (Figure 
17 b). 
 
Figure 17. Mammary cell lines secrete IL6 and sIL6R. (A) MCF10A cell line produces soluble IL6R 
and IL6 (IL6 * p= 0.02; sIL6R ****p<0.0001, two- tailed unpaired t-test); (B) HME wt cells secrete IL6 
and sIL6R in a cell density depending mode (IL6 level at 100% confluence vs. IL6 level at 30% 
confluence *p=0.016, two- tailed unpaired t-test). Results were confirmed in two independent 
experiments using technical replicates (n=2). 
This phenomenon suggested a density control mechanism of IL6 signaling in 
HME wt cells. If true, than mammary cells, which contain activated IL6 signaling 
should regulate the expression of IL6 and IL6R as a part of observed feed-back loop. 
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3.4. The activation of the PI3K/Akt signaling pathway inhibits IL6 and IL6R 
expression in mammary cells  
 
The IL6 signals via activation of different pathways, the JAK/STAT3, SHP-2/Ras and 
PI3K/Akt pathways (Grivennikov and Karin, 2008). Therefore, the observed 
differences in mRNA and protein expression of IL6 and IL6R between MCF10A and 
HME wt cells may result from the activation of different downstream signaling 
pathways that may render some cells independent form the availability of IL6/IL6R. 
To test this IL6 and IL6R expression was assessed in HME cells in which PI3K/Akt 
signaling was over-activated. 
HME PIK3CA ex20, carrying mutatation in exon 20, and HME shPTEN, displaying 
low PTEN down-regulated by short hairpin RNA, have constitutively activated 
PI3K/Akt signaling. From both cell lines single cells were isolated and their 
transcriptom was assessed for the expression of IL6 and IL6R. Interestingly, the 
activation of PI3K/Akt signaling pathway resulted in reduced number of IL6 and IL6R 
expressing cells (Figure 18 a-b), suggesting regulation of IL6 signaling/trans-
signaling by the PI3K/Akt signaling network. 
Since, activation of IL6 signaling had enhanced sphere forming ability (see 3.3.1), 
it was tested whether the activation of the downstream PI3K/Akt signaling in HME 
cells results in increased sphere forming ability of HME cells when propagated under 
anchorage independent conditions. Indeed, HME shPTEN and HME PIK3CA ex 20 
cells formed considerably higher number of spheres compared to wt cells indicating 
that sphere forming ability induced by IL6 may be maintained via PI3K/Akt signaling 
pathway (Figure 18 c).  
The reduced number of cells expressing IL6 and IL6R in HME PIK3CA ex20 
and HME PTEN cells compared to HME wt cells suggested that the activation of 
downstream effectors in IL6 signaling pathway reduces expression of IL6 and IL6R 
and induces propagation and survival of cells under anchorage independent 
conditions. 
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Figure 18. IL6 and IL6R expression in HME wt cells and cells with PIK3CA mutation and PTEN 
knockdown. Messenger RNA of single HME wt, HME PIK3CA ex.20 and HME PTEN cells were 
isolated and reversely transcribed.  Assessment of (A) IL6 and (B) IL6R expression was evaluated 
(p=0.016, Fisher’s exact test); (C) Sphere forming ability of HME cells alternated for PI3K/Akt signaling 
(HME wt vs. HME shPTEN p=0.016, two- tailed unpaired t-test; HME wt vs. HME PI3KCA p=0.142, 
two-tailed unpaired t-test). Results represent mean of 3 independent experiments (n=3), each 
performed using technical replica (n=3).  
The results obtained from analysis of mammary cell lines suggested that IL6 
trans-signaling influences proliferation and survival of mammary stem and progenitor 
cells under anchorage independent conditions via PI3K/Akt signaling.  
Obtained results suggested that IL6 trans-signaling is triggered in an autocrine 
and paracrine way in mammary cells. This finding raised a concern that utilization of 
epithelial cell lines may not reflect cellular complexity of the adult mammary gland 
and thus may not address contribution of various cells to IL6 trans-signaling 
activation. Therefore, the next experiments tried to address the influence of IL6 
(trans-) signaling in normal mammary gland. 
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3.5. IL6 signaling in the adult human mammary gland 
 
I tried to assess the effect of IL6 signaling in human adult mammary gland. The 
obtained results suggested that IL6 signals in mammary cell lines via trans-signaling. 
Therefore, I tried to address how IL6 signals in adult mammary gland and what is the 
contribution of various cells to IL6 trans-signaling.  
3.5.1. Mammary gland does not contain cellular population with 
membrane bound IL6R 
 
Mammary glands of the healthy donors undergoing breast reductions were used to 
investigate the effect of IL6 signaling in mammary stem and progenitor cells. It was 
first tested whether the IL6 signaling in the mammary gland is maintained trough 
membrane bound IL6R. Mammary tissue specimens cleared of fat tissue were 
mechanically and enzymatically digested after macroscopic exclusion of breast 
cancer by a pathologist (Figure 19 a). Cells from the digested tissue were stained 
with an antibody directed against membrane bound IL6R. FACS analysis 
demonstrated that cells which compose adult mammary glands do not express 
membrane bound IL6R (Figure 19 b).  
To exclude that IL6R is expressed by a very small subpopulation that might escape 
detection in bulk tissue adult mammary stem and progenitor cells were enriched by 
mammosphere culture and grown for two passages. The secondary mammospheres 
were then dissociated and stained against membrane bound IL6R.  
The FACS analysis suggested that the cells comprising secondary mammospheres 
do not express membrane bound IL6R (Figure 19 b). 
Thus membrane bound IL6R could neither be detected on the surface of cells 
comprising the secondary mammospheres, nor on cells directly isolated from 
digested tissue specimen. The lack of IL6R surface expression in mammary cells 
suggested that the IL6 signaling in the adult mammary gland is maintained via trans-
signaling. 
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Figure 19. Evaluation of the IL6R expression in the adult mammary gland. (A) Mammary glands 
of healthy donors were digested and propagated under anchorage independent conditions; (B) 
Positive control - expression of the membrane bound IL6R in blood cells of a healthy donor; (C) Cells 
comprising the adult mammary gland do not express membrane bound IL6R; (D) Cells obtained after 
tissue digestion were under 3D conditions. Biotinilated anti-IL6R antibody, UV-4 clone and mouse 
IgG1 κ, isotype control were used for FACS analysis. Results were confirmed in 3 independent 
samples (n=3).  
3.5.2. Mammary gland contains cellular populations which enable IL6 
trans-signaling 
 
IL6 trans- signaling in normal mammary gland is only possible if sIL6R and IL6 are 
expressed by any cellular population present in healthy organ.  
Cells obtained after mammary gland digestion represent many different cell types 
in different differentiation stages. I therefore investigated which cells express IL6 and 
IL6R transcripts and thus enable IL6 trans-signaling.  
First, the mRNA of laser-microdissected differentiated mammary ducts (DfMD) were 
globally amplified and IL6 and IL6R mRNA expression was assessed by gene 
specific PCR. Interestingly, none of the analyzed donors (n=3) expressed IL6 and 
IL6R (Figure 20 a-b), suggesting that these genes may be transcribed only by stroma 
or undifferentiated epithelial cells. Next, it was tested whether mammospheres 
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express IL6 and IL6R (Figure 20 a-b). Interestingly, both messages were detected 
when cells were propagated under conditions selecting for stem and progenitor cells. 
Therefore, undifferentiated cells may enable IL6 trans-signaling in the adult 
mammary gland. 
Moreover, as the adult mammary gland is consisted of developed stroma I 
tried to assess contribution of stroma in maintaining IL6 trans-signaling in adult 
human mammary gland. Therefore, mammary fibroblasts were isolated and 
propagated under defined culture conditions. The reversely transcribed mRNA 
isolated from single fibroblast was analyzed. The results indicated that 100% of 
analyzed cells express IL6 mRNA while IL6R mRNA was found in 30% of cells 
(Figure 20 a-b). Testing for the presence of IL6 and IL6R protein in the media 
confirmed high levels of IL6 expression by propagated fibroblasts (Figure 20 c). In 
addition, sIL6R protein could not be detected by analysis of fibroblast media.  
 
Figure 20. IL6 and IL6R expression in the adult mammary gland. Digested mammary gland, 
mammospheres and terminally differentiated mammary ducts (DfMD) after laser- microdissection were 
examined for the expression of the (A) IL6 and (B) IL6R expression; (C) IL6 production and secretion 
by mammary fibroblasts. Results obtained from 9 independent tissue specimens (n=9).   
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Taken together these data suggested that the IL6 signals via trans-signaling 
mechanism in the adult mammary gland. Moreover, the results suggested that IL6 
trans-signaling is maintained by fibroblasts and adult mammary stem and progenitor 
cells.  
In the following work I explored the role of IL6 trans-signaling in normal 
mammary cells.   
3.5.3.  IL6 trans-signaling in adult mammary stem and progenitor cells 
 
IL6 signaling in the adult mammary gland is maintained via trans-signaling where 
mammary undifferentiated cells and mammary fibroblasts produce IL6 and sIL6R. 
The impact of the IL6 trans-signaling on the mammary gland was studied in regard to 
stem and progenitor cells. 
3.5.3.1. IL6 signaling induces proliferation of adult mammary stem 
and progenitor cells 
 
The expression of sIL6 by adult mammary stem and progenitor cells suggested that 
addition of external IL6 may trigger IL6 trans-signaling in adult mammary stem and 
progenitor cells. Therefore, the impact of IL6 trans-signaling on mammosphere 
formation was investigated.  
For this, the mammary glands of healthy donors were dissociated and propagated 
under anchorage independent conditions. Briefly, after tissue digestion cells were 
propagated under anchorage independent conditions in mammosphere medium 
(MSM) or MSM supplemented with IL6. Primary mammospheres were passaged 7-
10 days post tissue digestion and further propagated in MSM or in MSM 
supplemented with IL6. The influence of IL6 trans-signaling activation was assessed 
by comparing the number of observed mammospheres and the average 
mammosphere size (Figure 21 a). 
The mammary cells supplemented with IL6 during the second passage formed 
50% more mammospheres compared to cells grown in control medium. Interestingly, 
addition of IL6 over two passages did not increase total mammosphere numbers 
(Figure 21 b). 
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The proliferative capacity of single mammospheres was measured by assessing the 
change in sphere diameter. Mammospheres supplemented with IL6 during the 
second passage were on average 16% bigger compared to mammospheres 
propagated in the medium without IL6 (Figure 21 c). However, the diameter of the 
secondary mammospheres supplemented over two passages with IL6 could not be 
measured because many mammospheres appeared to have fused due to their large 
size. 
 
Figure 21. IL6 stimulates mammosphere propagation. (A) Experimental strategy. After tissue 
digestion, cells were propagated in mammosphere medium (MSM) or in MSM supplemented with IL6 
(IL6). After primary mammospheres were formed, mammospheres were digested and further 
propagated in absence (MSM) or presence (IL6) of IL6. The overall number and size of the secondary 
mammosphere were evaluated; (B) The number of secondary mammospheres increased after 
application of IL6 during the second passage (p= 0.002, two- tailed unpaired t-test); (C) IL6 influenced 
proli feration of single mammosphere measured by the fold change of the mammosphere diameter (p< 
0.0001, two- tailed unpaired t-test). Results are obtained from 7 independent tissue specimens (n=7).  
Taken together, application of IL6 triggered IL6 trans-signaling what resulted in 
increased proliferation rate of the adult mammary stem and progenitor cells.  
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3.5.3.2. IL6 trans-signaling induces proliferation of adult mammary 
stem and progenitor cells 
 
While the effect of externally added IL6 is most likely mediated via soluble IL6R and 
trans-signaling (see previous data on IL6R and IL6 mRNA and protein expression), I 
directly tested whether mammary stem and progenitor cells are responsive to IL6 
trans-signaling. For this I used Hyper-IL6 (HIL6), a fusion protein of IL6 and sIL6R.  
The mammary tissue of healthy donors was dissociated to a single cell level 
and propagated under anchorage independent conditions over two passages. The 
cytokines (IL6 and HIL6) were applied on a day of mammary cell isolation or after the 
first passage. The influence of the IL6 trans-signaling in adult mammary stem cells 
was measured by the number of propagated secondary mammospheres, while the 
effect of IL6 trans-signaling on progenitor cells was measured by average fold-
change in diameter of the secondary mammospheres (Figure 23 a). Untreated cells 
(MSM) were used as experimental control. Although, the equal numbers of cells were 
plated after tissue digestion, mammary cells supplemented with HIL6 over two 
passages showed the highest mammosphere number indicating the influence of IL6 
trans-signaling in adult mammary stem cells (Figure 23 a). Moreover, IL6 trans-
signaling induced higher proliferation of mammospheres compared to untreated cells 
measured by mammosphere diameter (Figure 23 c). The size of the secondary 
mammospheres supplemented with HIL6 over two passages could not be evaluated 
due to frequent fusion of large mammospheres. However, the profound HIL6 effect 
on mammosphere diameter suggested that HIL6 induced proliferation of progenitor 
cells (Figure 22 and Figure 23). 
 
Figure 22. Activation of IL6 trans-signaling by HIL6 application induces increased 
mammosphere number and size.  
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Figure 23. IL6 trans-signaling stimulates proliferation of mammary stem and progenitor cells. 
(A) Experimental strategy. After tissue digestion, cells were propagated in mammosphere medium 
(MSM) or in MSM supplemented with IL6 or HIL6. After primary mammospheres were formed, 
mammospheres were digested and further propagated in absence (MSM) or presence IL6 or HIL6. 
The overall number and size of the secondary mammosphere were evaluated; (B) HIL6 induced the 
outgrowth of the secondary mammospheres; (C) IL6 trans-signaling induced proli feration of the 
secondary mammospheres (**** p< 0.0001; *** p=0.0001, two- tailed unpaired t-test). The # indicates 
that the average diameter was not measurable due to mammosphere fusions. Results are obtained 
from 7 independent tissue specimens (n=7).  
 Activation of IL6 trans-signaling induced proliferation of mammary stem and 
progenitor cell what raised a concern that IL6 trans-signaling might affect the basic 
biological features of mammary stem and progenitor cells, such as: differentiation 
ability, asymmetrical cell division and self-renewal. 
3.6.  IL6 trans-signaling preserves and promotes the functional phenotype of 
stem and progenitor cells 
 
Since the data showed that activation of IL6 signaling affects survival and 
proliferation of human mammary stem and progenitor cells, the effect of the IL6 trans-
signaling on stem and progenitor cell phenotype was further evaluated.  
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3.6.1. IL6 trans-signaling triggers mammospheres self-renewal 
 
The enhanced proliferation of mammospheres activated for IL6 trans-signaling raised 
the question whether the stimulated proliferation of stem and progenitor cells might 
reduce the self-renewal capacity of the adult mammary stem cells. 
Mammospheres were propagated under anchorage independent conditions 
either in mammosphere medium (MSM) or MSM supplemented with HIL6. The 
mammosphere self-renewal ability was measured by the ability of cells to form 
mammospheres of higher passages after mammosphere dissociation and re-plating. 
Mammospheres were passaged once a week. Mammospheres propagated in the 
presence of the HIL6 survived up to 6 passages after initial tissue dissociation, 
suggesting that IL6 trans-signaling preserves the self-renewal ability of human 
mammary stem and progenitor cells. Moreover, mammary cells propagated in 
absence of HIL6 could be maintained for 4 weeks. This finding suggests that IL6 
trans-signaling promoted self-renewal in mammary stem cells. 
 
Figure 24. IL6 trans-signaling preserves and induces mammosphere self-renewal. 
Mammospheres were propagated either in MSM or in MSM supplemented with HIL6. Obtained results 
were confirmed in 3 independent tissue specimens (n=3). 
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3.6.2. Activation of the IL6 trans-signaling does not reduce ability of the 
mammary stem and progenitor cells to differentiate 
 
3.6.2.1. Ability of HIL6-treated cells to differentiate in vitro  
 
The mammary stem and progenitor cells differentiate in Matrigel© into tubular-duct 
lobular units (TDLU) and in acinar structures. To test whether activation of IL6 trans-
signaling affects in vitro differentiation ability, the secondary mammospheres 
propagated in MSM or in MSM supplemented with HIL6 were propagated under 
differentiation conditions in 3D Matrigel©. The secondary mammospheres were 
dissociated and plated in “sandwich” embedding model (described in chapter 3.2.4). 
The differentiation ability was evaluated three weeks post-plating by counting acinar 
and TDLU differentiation structures. No difference was observed for the cells 
propagated in the presence or absence of HIL6 in mammosphere medium.  
These results indicate that IL6 trans-signaling does not influence the in vitro 
differentiation ability of the secondary mammospheres (Figure 25).  
 
Figure 25. Mammosphere in vitro differentiation in 3D Matrigel
©
. The secondary mammospheres 
were embedded in Matrigel
©
. Differentiation ability was evaluated three weeks post embedding. 
Mammospheres were propagated either in mammosphere medium (MSM) or in MSM supplemented 
with HIL6 (p= 0.20 TDLU of MSM vs. TDLU MSM+HIL6; p= 0.78 Acinar structures MSM vs. 
MSM+HIL6; two- tailed unpaired t-test). Results were obtained using tissue specimens of 2 donors 
(n=2). Experiments were performed in technical duplicates.  
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3.6.2.2. Activation of IL6 trans-signaling in mammospheres does not 
influence their differentiation ability  in animal hosts 
 
To test the differentiation ability of the secondary mammospheres in vivo, the 
mammary cells isolated from human donors were first propagated in MSM 
supplemented with HIL6 and after generation of secondary mammospheres 
inoculated into NSG mice according to the previously established protocol (3.2.5.3). 
The mammary fat-pads of NSG mice were examined 8 weeks post-inoculation.  
The analyzed mammary fat-pads contained differentiated epithelial structures 
resembling human mammary ducts (Figure 26 a). The human origin and the 
differentiated luminal phenotype of observed cells was confirmed by 
immunohistochemistry using a human specific antibody against CK18, an antigen 
expressed in differentiated mammary ducts (Figure 26 b). 
 
Figure 26. In vivo differentiation of mammospheres activated by IL6 trans-signaling. The 
secondary mammospheres co-mixed with C3H10T1/2 murine fibroblasts were injected into pre-
cleared mammary fat-pad of NSG mice. Eight weeks later mammary fat-pads were analyzed for the 
presence of human mammary glandular structures. (A) Human mammary epithelial ductual structures 
in mouse mammary fat-pad; (B) observed epithelial cells expressed human CK18. The results were 
obtained using mammary tissue donated by two healthy donors (n=2). In total, six mice were included 
in the analysis.  
The ductal structures which were shown to express CK18 were further tested for their 
human origin by assessing the human origin of isolated DNA. For this, laser micro-
dissection of ductal structures was performed by P.A.L.M laser-microdissection 
microscope. Following DNA isolation by Mse PCR global genome amplification, a 
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PCR assay designed to amplify either unique human or mouse specific sequences 
was applied.  
Micro-dissected ducts clearly contained human specific genomic sequences of P53 
and pseudo cytokeratin 19 genes, while these sequences were not amplified in 
micro-dissected mouse tissue what further confirmed their human origin (Figure 27).  
 
Figure 27. Micro-dissected CK18 expressing cells are of human origin. DNA were isolated from 
micro-dissected (1, 2) CK18 expressing cells and (3) CK18 non expressing cells . PCR amplification of 
CK18 positive cells resulted in amplification of human specific sequences. (4) Mouse positive control; 
(5) Human positive control; (6) Negative control. 
Taken together, secondary mammospheres propagated in presence of HIL6 can 
differentiate in vivo demonstrating that IL6 trans-signaling does reduce the 
differentiation ability of mammary stem and progenitor cells. 
3.6.3. IL6 trans-signaling does not influence asymmetric cell division 
 
Adult mammary stem cells divide asymmetrically. The results of such cellular 
divisions are two daughter cells, one of which preserves the ability to self-renew, 
while the other cell differentiates into a faster dividing progenitor cell. 
The cell membrane of the dividing cell is shared among the daughter cells. Thus, 
when the cell membrane of mammary stem cells is labeled by an unspecific dye, the 
marker molecule will be shared among daughter cells and diluted upon each cell 
division (Figure 28 a). 
The mammary cells isolated from donated tissue specimens were labeled by 
fluorescent PKH26 marker. Anchorage independent environment enabled survival 
and propagation of undifferentiated cells. Two passages after labeling, it was 
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observed that mammospheres consisted of many unlabeled cells and rare, label 
retaining cells (LRC). The detection of LRC suggested that activation of IL6 trans-
signaling did not abolish asymmetric cell divisions of mammary stem cells (Figure 28 
b-c). 
 
Figure 28. IL6 trans-signaling preserve s the ability of stem cells to divide asymmetrically. (A) 
Mammary stem cells are slow cycling cells which divide into one slow cycling self-renewed stem cell 
and one faster dividing progenitor cell; (B) PKH26 labeling of cells isolated from the donor’s tissue 
specimens; (C) Detection of the slow dividing, label retaining cells (LRC) and faster dividing non LRC 
(nLRC), PKH26-negative cells. nLRC eventually diluted the dye to undetectable levels. The results 
were confirmed by utilizing 10 tissue specimens.  
 Taken together, the activation of IL6 trans-signaling enhances self-renewal 
capacity and proliferation of normal mammary stem and progenitor cells, while 
doesn’t influence their ability to differentiate and asymmetrically divide. Furthermore, 
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ability to identify stem and progenitor cells within single mammosphere by label 
retention provided an opportunity to assess the effect of IL6 trans-signaling on 
mammary stem and progenitor cells. 
3.7.  Activation of IL6 trans-signaling induces mammosphere forming ability 
of nLRC 
 
Secondary mammospheres can differentiate into all epitheli la lineages of a 
differentiated mammary gland. I used LRC and nLRC to narrow down the identity of 
mammary stem cells. 
3.7.1. nLRC are not able to form mammospheres unless IL6 trans-
signaling is activated 
 
LRC are rare and slow dividing cells and thus represent good candidates for 
mammosphere founder cells. To test whether LRC are able to form mammospheres, 
single LRC and non-LRC (nLRC) were transferred to a 96 well plate and monitored 
for a period of two weeks for a single cell survival and mammosphere formation 
(Figure 29 a). 
In total, 4 out of 97 plated single LRC proliferated and formed mammospheres 
indicating the ability of LRC to form mammospheres. However, nLRC of the 
mammospheres obtained from the same tissue donors (n=4) did not show the ability 
to form mammospheres (0/175) (Figure 29 b). 
The ability of mammary cells to secrete soluble factors such as cytokines, which 
could in turn stimulate cell proliferation, proposed that nLRC propagation in condition 
medium (CM), may be beneficial for mammosphere formation. CM is mammosphere 
medium which was used for propagation of mammary cells. In prior to use, CM was 
filtered trough 0,45 µm fi lters to omit the cellular presence. However, nLRC 
propagated in condition medium (CM) did not trigger mammosphere formation as 
none of the 180 plated cells formed mammospheres (Figure 29 b). 
Although nLRC cells were not able to form mammospheres, propagation of nLRC 
obtained from the same tissue specimens in mammosphere media supplemented 
with HIL6 resulted in mammosphere formation (5/179) suggesting important role of 
IL6 trans-signaling in mammosphere formation (Figure 29 b). 
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Obtained results suggested that mammosphere forming ability of LRC may be a 
result of an autocrine activated IL6 trans-signaling. Therefore, the co-expression of 
IL6 and IL6R in LRC and nLRC was tested. IL6 and IL6R expression was assessed 
in nLRC and LRC isolated from 9 tissue specimens. The percent of the cells 
expressing IL6 or IL6R was higher in case of LRC compared to nLRC (Figure 29 c). 
Next, the co-expression of IL6 and IL6R in nLRC and LRC was assessed. The result 
indicated a tendency of LRC to co-express IL6 and IL6R more frequently compared 
to nLRC (LRC vs. nLRC=13% vs. 6%) (Figure 29 d). 
 
Figure 29. LRC and HIL6 treated nLRC encompass mammosphere forming ability. (A) 
Experimental strategy. LRC and nLRC were isolated from the secondary mammospheres, plated in a 
96-well plate and observed for 2 weeks for a mammosphere formation or cell survival; (B) LRC and 
HIL6 treated nLRC formed mammospheres. nLRC maintained in condition medium without HIL6 did 
not develop mammospheres; (C) LRC and nLRC express IL6 and IL6R; (D) LRC and nLRC co-
express IL6 and IL6R (p= 0.2 two-sided Fisher’s exact test). The results were obtained using 15 tissue 
specimens (n=15).  
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The acquisition of the mammosphere forming ability, the characteristic of stem cells, 
by triggering IL6 trans-signaling in progenitor cells suggested the influence of IL6 
signaling in mammary cell hierarchy. Cellular hierarchy is also in particular important 
for breast cancer and cancer stem cell concept and therefore, I tried to address the 
impact of IL6 trans-signaling in cancer stem and non stem cells. 
3.8. IL6 trans-signaling in breast cancer 
 
IL6 trans-signaling affects stem and progenitor cells proliferation and self-renewal, 
while it maintains stem cell characteristics such as, asymmetrical cell division and 
differentiation ability. Moreover, activation of the IL6 trans-signaling enables nLRC to 
acquire the mammosphere forming ability what is rather the characteristic of LRC. 
Therefore, IL6 trans-signaling may also have a role in propagation and proliferation of 
cancer stem cells (CSC) and thereby affect tumor growth. 
3.8.1. Breast cancer cells do not contain membrane-bound IL6R 
 
Breast cancer cell lines derived from primary tumor and metastasis (BT474, MCF7, 
SKBR3, T47D, MDA-MB-231) were used to test whether IL6 signals in cancer cells 
via membrane bound IL6R.  
The cancer cells were propagated under conventional 2D culture conditions or 
under 3D mammosphere conditions. After cell detachment and disaggregation, cells 
were stained with antibodies against the IL6R. None of the examined cell lines was 
found to express the membrane bound form of the IL6R (Figure 30 a-e) suggesting 
that IL6 signaling might be maintained in breast cancer cell lines via trans-signaling. 
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Figure 30. The expression of IL6R in breast cancer cell lines. The expression of membrane-bound 
IL6R was assayed by FACS. (A) BT474, (B) MCF7, (C) SKBR3, (D) T47D, (E) MDA-MB-231, (F) 
Whole blood of a healthy individual was used as a positive control. Biotinilated anti-IL6R antibody, UV-
4 clone and mouse IgG1 κ, isotype control were used for FACS analysis. The results were confirmed 
by independent experiments (n=2).  
3.8.2. MDA-MB-231 cells express IL6 and IL6R 
 
The lack of the membrane bound IL6R in cancer cells raised a question whether 
breast cancer cells exploit IL6 trans-signaling. To test this hypothesis transcription of 
IL6 and IL6R in breast cancer cells were assessed. MDA-MB-231 cells were 
propagated under 2D or 3D conditions and mRNA of single cancer cells were 
isolated and after reverse transcription tested for the presence of IL6 or IL6R 
transcripts by gene specific PCR. Results showed that MDA-MB-231 cells 
propagated under the 3D conditions expressed in a higher level IL6 and IL6R 
compared to cells propagated as a 2D monolayer (Figure 31 a). 
 Interestingly, the activation of IL6 signaling by the addition of external IL6 
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resulted in the higher number of obtained spheres indicating that observed cells 
secrete sIL6R. The effect in the sphere formation ability and cancer cell proliferation 
was even more striking if the trans-signaling was directly triggered by HIL6 
application. On the other hand, blocking of the IL6 signaling resulted in reduced 
numbers of mammospheres and reduced proliferation shown by the mammosphere 
size (Figure 31 b-c).  
 
Figure 31. IL6 trans-signaling in MDA-MB-231 cells. (A) MDA-MB-231 cells express IL6 and IL6R 
and thus enable IL6 trans-signaling; (B) IL6 trans-signaling induced sphere formation and (C) IL6 
trans-signaling stimulated cell proli feration under 3D conditions. Results represent a mean of 3 
experiments (n=3), each performed in technical replicates. (*** p= 0.0001, two- tailed unpaired t-test; 
**** p< 0.0001, two- tailed unpaired t-test).  
The obtained results indicated that IL6 trans-signaling activates proliferation and 
survival of MDA-MB-231 cells under anchorage independent conditions and thus may 
affects their cancer stem cell phenotype. 
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3.8.3. IL6 trans-signaling stimulates tumor formation of MDA-MB-231 
cells 
 
Cancer stem cells are defined as cells able to grow tumors in animal hosts. Since IL6 
trans-signaling promoted survival and proliferation of cancer cells under anchorage 
independent conditions the impact of activated IL6 signaling for MDA-MB-231 tumor 
formation in vivo was tested.  
IL6 trans-signaling was activated by incubation of the cells with HIL6, while IL6 
signaling was blocked by the application of blocking antibody. The influence of IL6 
trans-signaling on tumor formation, tumor size and metastasis formation were 
analyzed by inoculation of cells pre-incubated with either HIL6 or blocking antibody 
(Figure 32 a). 
The MDA-MB-231 cells were propagated under 2D conditions and and treated either 
with HIL6 or blocking antibody 4 hours before inoculation. The pre-treated MDA-MB-
231 cell were inoculated into pre-cleared mammary fat-pad of NSG mice (Figure 32 
a). The effect of IL6 trans-signaling was evaluated seven weeks post-inoculation.  
The tumors of mice inoculated with HIL6 pre-treated MDA-MB-231 cells were in 
average twice bigger compared to tumors of a control group (HIL6 vs. PBS = 425 
mm3 vs. 237 mm3). Interestingly, despite the differences in a tumor growth, there 
were no evidences that IL6 trans-signaling influences metastasis formation. 
The obtained results proposed that IL6 trans-signaling induces CSC 
propagation in vivo and influences tumor outgrowth. 
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Figure 32. IL6 trans-signaling induces tumor formation in vivo. (A) Experimental strategy. MDA -
MB-231 cells were treated for 3 hours with HIL6, IL6 singling blocking antibody or PBS. Mice were 
analyzed seven weeks post inoculation. (B) Activation of the IL6 trans-signaling in MDA-MB-231 cell 
line induced formation of tumors with higher volume compared to PBS control (PBS vs. HIL6 p= 0.04; 
anti-IL6 vs. HIL6 p=0.004; two- tailed unpaired t-test). Results were obtained from a group of 15 mice 
(n=15).  
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3.8.4.  Activation of IL6 (trans)-signaling does not induce proliferation of 
MCF7 derived CSC 
 
Since activation of PI3K/Akt signaling in HME cells resulted in higher sphere forming 
ability and decreased number of IL6 and IL6R expressing cells, I aimed to explore 
whether IL6 induces CSC phenotype as observed in MDA-MB-231 cells via 
downstream increase in PI3K/Akt signaling. 
MCF7 cancer cells do not express membrane bound IL6R (Figure 33 a) and have 
constitutive increase in PI3K/Akt signaling due to the activated mutation in exon 9 of 
PIK3CA and thus represent a good model for testing whether IL6 induces CSC 
phenotype via increase in PI3K/Akt signaling. 
Transcriptom of MCF7 cells propagated under 2D and 3D conditions were isolated 
and reversely transcribed. The IL6 and IL6R expression assessment indicated that 
low number of MCF7 cells express IL6 mRNA (1/22, 5% in 2D) while number of cells 
expressing IL6R was extensively increased when cells were propagated under 3D 
conditions (2D= 1/22 vs. 3D= 12/12) (Figure 33 b). Although assessment of 
transcription suggested that IL6 trans-signaling could be triggered by expressional 
activity of MCF7 cells, analysis of growth media showed that MCF7 cells secrete low 
levels, if any of IL6 (Figure 33 c). Interestingly, MCF7 cells grown under anchorage 
independent conditions expressed low levels of sIL6R what was in line with results 
obtained from transcriptom analysis (Figure 33 b c). 
As MCF7 cells produce low levels of IL6 and sIL6R, I hypothesized that activation of 
IL6 trans-signaling by application of HIL6 may affect CSC phenotype as observed in 
MDA-MB-231 cells. 
MCF7 cells were propagated 7 days under anchorage independent conditions in 
mammosphere medium supplemented by HIL6 or IL6. Interestingly, activation of IL6 
trans-signaling by addition of HIL6 or IL6 did not resulted in increased number of 
observed spheres. 
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Figure 33. IL6 signaling in MCF7 cells. (A) MCF7 cells propagated under anchorage independent 
conditions (3D) or under 2D conditions  do not express membrane bound IL6R as shown by flow 
cytometry; (B) Assessment of IL6 and IL6R expression in single MCF7 cells propagated under 2D 
conditions or sphere propagated under 3D conditions (IL6R expression 2D vs. 3D p<0.0001, Fisher’s 
exact test); (C) Assessment of IL6 and sIL6R protein in growth media of MCF7 cells propagated under 
2D or 3D conditions (n=3, IL6 2D vs. 2D media p= 0.938, two- tailed unpaired t-test; n=3, sIL6R 3D vs 
3D media p=0.002; two- tailed unpaired t-test); (D) IL6 trans-signaling does not influence sphere 
forming ability of MCF7 cells. MCF7 cells were propagated in mammosphere medium (MSM), MSM 
supplemented with IL6 or MSM supplemented with HIL6. (MSM vs IL6 p= 0.589; MSM vs. HIL6 
p=0.836; IL6 vs. HIL6 p=0.777 two- tailed unpaired t-test). Results represent mean of 3 experiments 
(n=3), each experiment was performed in technical replicates. 
 
Taken together these data suggest that activation of IL6 trans-signaling in MCF7 
cells, breast cancer cells which have constitutively activated PIK3/Akt signaling, does 
not influence CSC phenotype.
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4. Discussion 
 
The adult mammary gland is a complex organ composed of epithelial derived ducts 
surrounded by connective tissue and adipose tissue lobes (Sheffield, 1988). The 
development of the human mammary gland is driven by mammary stem cells and 
occurs in three distinct and differentially regulated stages: embryonic, pubertal and 
adult (Anbazhagan et al., 1991; Gjorevski and Nelson, 2011; Howard and Gusterson, 
2000). Although mammary gland development starts early during ontogeny, most of 
developmental processes occur postnatal. More precisely, mammary glands reach 
functional maturity at late pregnancy during a process known as lactation (Radisky 
and Hartmann, 2009). At this stage the mammary gland is mostly composed of 
secretory terminally differentiated epithelia (>90%) and low numbers (0,2-0,45%) of 
undifferentiated adult stem and progenitor cells (Alvi et al., 2002; Borellini and Oka, 
1989). Adult mammary stem and progenitor cells enable cyclic bursts of proliferation 
and differentiation which take place at each pregnancy cycle (Van Keymeulen et al., 
2011). However, these cell populations are also a source of various breast 
abnormalities. Deregulation of the both stromal and epithelial stem cells cause breast 
hypertrophy, which manifests as abnormal breast sizes, or cancer (Dancey et al., 
2008; Dehner et al., 1999; Ginestier et al., 2007b). 
Breast cancer accounts as the most frequent cancer type among women. Only in 
2008, breast cancer caused 458 503 deaths worldwide (WHO, 2008). It has been 
proposed that breast cancer development is driven by a small population of cancer 
stem cells (CSC), rare tumor clones able to grow tumors in animal hosts which also 
can differentiate into non-CSC (Clarke et al., 2006). The current CSC concept 
suggests that disease relapse and later progression is largely due to the intrinsic 
therapy resistance of CSC (Gupta et al., 2009). Although the first experiments 
suggested that CSC are transformed normal stem cells, the CSC concept also 
suggests that the target cell of malignant transformation may be differentiated cells 
which acquire malignant and stem cells properties by the transformation process 
(Bjerkvig et al., 2005).  
It was suggested that acquisition of CSC phenotype is facilitated trough activation of 
4. Discussion 
 
89 
 
epithelial to mesenchymal transition (EMT), a developmental process that enables 
epithelial cells to acquire a mesenchymal phenotype. This data suggest that EMT not 
only comprises the ability to migrate but also stem cell properties such as self -
renewal and differentiation through activation of a set of transcription factors  (Mani et 
al., 2008). The activation of EMT is a result of a complex interaction of normal and 
cancer cells with the micro-environment composed of stromal and infiltrating cells 
and adjacent extracellular matrix (Hanahan and Weinberg, 2011; Lee et al., 2007). 
Moreover, the extracellular matrix has been described as a functional unit of the 
mammary gland, which regulates mammary gland differentiation, development and 
proliferation (Schedin et al., 2004; Wicha et al., 1980). Extracellular matrix maintains 
paracrine and autocrine signaling networks by storing and supplying cells with 
soluble factors such as Interleukin 6 (Bonafe et al., 2012; Maller et al., 2010).  
IL6 signals in mammary cells via soluble IL6 receptor 
Despite considerable knowledge about the development and the regulation of 
mammary gland function under physiological and pathophysiological conditio ns, the 
effect of Interleukin 6 (IL6) in normal and cancer stem cells is largely unknown. IL6 is 
a multifunctional cytokine which has a role in many diseases (Kishimoto, 2005). IL6 
signaling is activated through IL6 binding to specific membrane-bound IL6 receptor 
(IL6R) while the subsequent interaction of IL6-IL6R complex with gp130 leads to 
signal initiation (Kishimoto, 2005; Korkaya et al., 2011; Scheller et al., 2006). 
Sansone and colleagues demonstrated that activation of IL6 signaling induces an 
autocrine loop which triggers self renewal of normal mammary stem and progenitor 
cells in mammary glands (Sansone et al., 2007). Therefore, I tried to assess whether 
mammary stem and progenitor cells regulate their phenotype via higher expression of 
membrane-bound IL6R compared to more differentiated cells. Stem and progenitor 
cells were enriched by propagation of cells under 3D, anchorage independent growth 
conditions (Dontu et al., 2003a; Sansone et al., 2007) and compared to cells 
propagated under conventional 2D growth condition. Surprisingly, assessment of 
membrane bound IL6R expression by flow cytometry suggested that neither MCF10A 
nor HME wt cells express membrane bound IL6R. Moreover, enrichment of stem and 
progenitor cells did not result in detectable membrane-bound IL6R expression in both 
cell lines. This finding challenged my observation that application of IL6 induces 
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sphere-forming ability of HME wt and MCF10A and thus stimulates stem and 
progenitor phenotype. Moreover, lack of membrane bound IL6R on MCF10A and 
HME wt cells challenged the current view on IL6 signal transduction in mammary 
cells as it has been suggested that IL6 signals in mammary cells via membrane 
bound IL6R (Grivennikov and Karin, 2008). 
An alternative mechanism to activate IL6 signaling involves trans-signaling. 
Expression of IL6R is not restricted only to a membrane bound form, analysis of 
human sera confirmed presence of soluble form of IL6R (sIL6R) (Montero-Julian, 
2001) which can trigger mechanism known as IL6 trans-signaling (Scheller et al., 
2006). I therefore investigated whether mammary cells express IL6 and sIL6R and 
thus utilize IL6 trans-signaling. The assessment of IL6R transcription showed that 
normal mammary cells, MCF10A and HME wt cells, express IL6R and IL6 mRNA. 
Subsequently, both proteins could be detected in media of the cells indicating that all 
the pre-requisites for trans-signaling are available. The assessment of IL6 and sIL6R 
mRNA co-expression suggested that due to the low frequency of cells able to co-
express IL6 and sIL6R, IL6 trans-signaling in mammary cells is rather maintained in a 
paracrine way or rarely in an autocrine manner by co-expressing cells. 
For these analysis, it cannot be excluded that sensitivity of flow cytometry was 
insufficient to detect low surface receptor expression (Kishimoto, 2005). However, 
even in such a scenario IL6 trans-signalling should be considered as a mechanism of 
an autocrine/paracrine regulation in mammary cells. Indeed, activation of IL6 trans-
signalling by addition of IL6 or Hyper-IL6 (HIL6), a fusion protein of IL6 and sIL6R, 
had an effect on mammary cell propagation under anchorage independent 
conditions. These findings pointed to a direct impact of IL6 trans-signalling on 
mammary stem and progenitor cells. 
IL6 trans-signaling activates propagation of normal mammary stem cells  
IL6 can activate stem cell signalling pathways such as Notch signalling pathway in 
cancer cells. This pathway is particularly involved in the formation of mammospheres 
(Sansone et al., 2007). The mammosphere assay enables propagation of mammary 
stem and progenitor cells (Dontu et al., 2003a) in form of spherical colonies, which 
arise from a single stem cell (Liu et al., 2008). It is assumed that the number of 
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mammospheres represents the initial number of stem cells, while the mammosphere 
size represents the proliferative capacity of stem and progenitor cells contained 
within the single colony. 
The data presented here suggest that IL6 trans-signalling has a broader effect. It 
activates propagation of the non cancer stem cells and enables them to form 
mammospheres, since activation of IL6 trans-signalling increased total 
mammosphere numbers and average mammosphere sizes. Inactivation of the IL6 
signalling pathway by IL6R blocking antibody affected the outgrowth of 
mammospheres, but did not result in total ablation of the mammospheres, suggesting 
that IL6 signalling is supportive, but not the only determining factor for the 
establishment of stem and progenitor phenotype. 
IL6 signals via activation of JAK/STAT, SHP2/Ras and PI3K/Akt signaling 
pathways (Kishimoto, 2005). Therefore, blocking an upstream effector of these 
pathways such as IL6 may not be sufficient for ablation of the stem cell phenotype. 
Interestingly, I found that up-regulation of the PI3K/Act signalling by activating 
mutations resulted in higher numbers of observed mammospheres, while IL6 and 
IL6R transcription was down-regulated. These experiments were performed using 
isogenic cell lines where the transformed normal mammary cell line HME had been 
modified by knocking in a mutated exon 20 of PIK3CA. In these cells I could not 
detect cells co-expressing IL6 and IL6R. The cross-regulation of the PI3K/Act 
signalling pathway and the IL6 signalling pathway in cancer cells might be of 
particular importance for breast cancers with deregulated PI3K pathway or higher IL6 
levels (Bachelot et al., 2003), as PIK3CA is one of the most frequently mutated genes 
in breast cancer (Adams et al., 2011).  On the other hand, it could well be that 
mutations of PIK3CA enable cancer cells to become independent of IL6 trans-
signalling. Therefore, it was important to assess whether trans-signalling has a 
physiological role in mammary glands. 
Since the adult mammary gland is composed of both epithelial and mesenchymal 
derived cells, IL6 trans-signalling may be triggered as a result of the secretory activity 
of different cell types. Indeed, it has been proposed that fibroblasts are the major 
source of IL6 in various organs and in cancer (Bonafe et al., 2012) and thus may 
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contribute to IL6 trans-signaling. I therefore explored the mechanism of IL6 trans-
signaling activation in normal adult mammary glands. 
Digested mammary glands were analyzed by FACS for the expression of membrane 
bound IL6R. The results indicated that normal adult mammary gland does not contain 
a cell population that expresses membrane bound IL6R. Therefore, I explored 
whether mammary gland is able to uti lize IL6 trans-signaling. Transcriptom analysis 
of cells isolated from the adult mammary gland indicated presence of cells 
expressing IL6 and IL6R suggesting that IL6 signaling is maintained in adult 
mammary glands via trans-signaling. Next, it was explored which of the cellular 
populations within adult mammary gland expresses IL6 and IL6R. Therefore 
transcriptoms of (1) terminally differentiated mammary cells; (2) adult mammary stem 
and progenitor cells and (3) normal mammary fibroblasts were analyzed for the 
expression of IL6 and IL6R. Surprisingly, although terminally differentiated mammary 
epithelial cells represent more than 90% of all epithelial cells within adult mammary 
glands (Stingl et al., 2005) they fail to express IL6 or IL6R. However, the same 
analysis suggested that IL6 trans-signaling is enabled in adult mammary gland due to 
expression of IL6 and IL6R by mammary fibroblasts, stem and progenitor cells. 
Moreover, mammary fibroblasts expressed high levels of IL6 as assessed by analysis 
of protein secreted in growth media. Mammary fibroblasts showed over 10 fold higher 
expression of IL6 compared to HME wt cells confirming that fibroblasts are one of the 
major sources of IL6 (Bonafe et al., 2012). Thus, it is suggested that IL6 trans-
signalling in adult mammary gland is maintained via trans-signaling. 
IL6 trans-signaling triggers a stem cell phenotype in mammary cells  
Activation of IL6 trans-signaling in fresh ex-vivo isolated mammary glands by addition 
of IL6 increased the number of mammospheres and induced their proliferative ability 
as measured by the mammosphere size. These data indicated that IL6 induces 
normal mammary stem/progenitor cell proliferation. However, IL6 trans-signaling in 
adult mammary gland could be generated with the help of mammary fibroblasts. 
Therefore, I aimed to assess the responsiveness of mammary stem and progenitor 
cells to IL6 trans-signaling via application of HIL6. Propagation of mammary stem 
and progenitor cells in presence of HIL6 substantially increased mammosphere 
formation and proliferation as measured by number of obtained mammospheres and 
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their size. Thus, mammary stem and progenitor cells readily respond to IL6 trans -
signaling. 
In the next step, I tried to address whether IL6 trans-signaling influences stem 
cells characteristics such as self-renew ability, differentiation capacity and ability to 
divide asymmetrically (Pece et al., 2010; Smalley and Ashworth, 2003). 
Self-renewal was measured by the ability of mammospheres to be serially passaged 
(Aceto et al., 2012). The normal adult mammary stem and progenitor cells can be 
maintained over several weeks under anchorage independent conditions until they 
ultimately stop propagating and undergo cellular senescence (Dontu et al., 2003a). 
HIL6 treated mammospheres were propagated up to 6  passages while non-activated 
cells were propagated for up to 4 passages. This result indicated that activation of IL6 
trans-signaling triggers self-renewal capacity of the adult mammary stem and 
progenitor cells. Furthermore, it specifies the findings of Sansone and colleagues 
who attributed similar effects in breast cancer cells to conventional signaling 
(Sansone et al., 2007).   
The differentiation ability of stem and progenitor cells was investigated in vitro by cell 
propagation in 3D Matrigel© and by differentiation of mammary stem and progenitor 
cells in immunodeficient mice (Lee et al., 2007; Proia and Kuperwasser, 2006).  
Quantification of the in vitro differentiation ability indicated that activation of IL6 trans-
signaling in adult mammary stem and progenitor cells preserves differentiation ability 
as shown by the formation of acini and TDLU structures. The small insignificant 
differences in overall numbers of the TDLU structures between HIL6 treated and 
untreated cells may be interpreted as a result of the experimental setting rather than 
reflects biology. Ultimately, human mammospheres propagated in presence of HIL6 
showed differentiation ability in vivo by forming complex structure resembling human 
adult mammary gland when inoculated in pre-cleared mammary fat-pad of NSG 
mice. Together, this data showed that IL6 trans-signaling does not negatively 
influence the differentiation ability of mammary stem cells. 
As an aside, the in vivo experiments led to a novel in vivo differentiation assay, which 
overcomes substantial experimental hurdles. Co-injection of murine fibroblasts 
instead of human hTERT immortalized fibroblasts led to significantly higher 
engraftment of normal human mammary stem cells and abolished the need for a two-
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step surgical transplantation protocol. The resulting protocol is fairly simple and might 
be used as an efficient and reproducible orthotopic xenotransplantation model in 
mammary gland biology. 
During asymmetrical stem cell divisions, stem cells give rise to two daughter 
cells of different phenotype. One cell is a stem cell with self-renewal ability, while the 
other daughter cell is a progenitor cell (Smalley and Ashworth, 2003). Based on the 
assumption that stem cells are rarely and slow dividing cells, I exploited a method 
introduced by Pece and colleagues to mammary stem cell biology (Pece et al., 2010). 
The protocol uses the ability of unspecific membrane dyes to mark cells which, upon 
division, provide each progeny with half of the dye. Thus, the marker molecule is 
diluted upon each cell division. Since stem cells (sphere forming cells) are slow 
dividing cells, asymmetrical division of mammary stem cells can be monitored by 
dilution of unspecific dye during mammosphere outgrowth in the majority of rapidly 
dividing progenitor cells (Pece et al., 2010), whereas rarely dividing stem cells would 
stay labeled (so called “label retaining cells”) over several culture passages. In these 
experiments, surgical specimen were digested, the epithelial cell fraction labeled with 
the unspecific fluorescent membrane dye PKH26 and propagated in mammosphere 
medium containing HIL6 or in control medium. Two weeks post labeling, HIL6 treated 
and untreated secondary mammospheres showed presence of rare label retaining 
cells (LRC) indicating that asymmetrical cell division is not affected by IL6 trans-
signaling. Therefore, it seems unlikely that the increase of mammospheres by HIL6 is 
caused via the generation of symmetrically dividing cells. 
IL6 trans-signaling induces stem cell phenotype in progenitor cells  
Consequently, I aimed to directly address role of IL6 trans-signaling in stem and in 
progenitor cells. Using the assay mentioned above, stem cells were identified as 
label retaining cells (LRC), while the label non-retaining cells (nLRC) were identified 
with progenitor cells. The functional difference between LRC and nLRC was 
assessed by the ability of single stem cells (LRC) to form mammospheres. While 
single LRC were able to form mammospheres, single nLRC were able to grow as 
mammospheres only when supplemented by HIL6. Obviously, IL6 trans-signaling 
modified the functional phenotype of progenitor cells by inducing stem-like 
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characteristics. Thus, the increased number of the secondary mammospheres 
observed upon activation of IL6 trans-signaling is a result of acquisition of 
mammosphere forming ability of progenitor cells rather than influence of IL6 trans-
signaling on mammary stem cells. Of interest, assessment of IL6 and IL6R 
expression revealed a tendency of LRC to co-express IL6 and IL6R, suggesting that 
physiological IL6 trans-signaling is involved in stem cell-renewal in an autocrine way. 
IL6 trans-signaling enables CnCS-CSC conversion in breast cancer 
Increased levels of IL6 in sera of breast cancer patients correlate with poor disease 
prognosis (Bachelot et al., 2003) what suggested that IL6 signaling plays an 
important role in shaping aggressive phenotype of breast cancer. This finding was 
supported by observations observation that malignant transformation may trigger IL6 
signaling (Iliopoulos et al., 2011). On the background of the CSC concept the results 
presented here suggested that IL6 trans-signaling acts upon progenitor cells and 
might affect the expansion of the CSC pool in breast cancer. Particularly, it may help 
non- stem cancer cells (CnSC) to acquire a CSC phenotype.  
I explored this hypothesis in MDA-MB-231 cell line, a metastatic cell line derived from 
pleural effusion of a donor diagnosed with breast cancer. MDA-MB-231 shows highly 
aggressive phenotype as shown by in vivo propagation in immunodeficient mice 
(Minn et al., 2005). The measurement of IL6 and IL6R expression in MDA-MB-231 
cells suggested that propagation of MDA-MB-231 cells under anchorage independent 
conditions triggers IL6 and IL6R expression. Thus, IL6 trans-signaling may be linked 
to the cancer stem cell phenotype in MDA-MB-231 cells. Moreover, activation of IL6 
trans-signaling by application of HIL6 resulted in considerable increased proliferation 
of MDA-MB-231 cells under anchorage independent conditions. When MDA-MB-231 
cells were bathed in HIL6 containing medium and subsequently transplanted into 
NSG mice, tumors grow much faster, while block of IL6 signaling by single shot 
treatment with blocking antibody resulted in decreased tumor volume. Interestingly, 
blocking IL6 signaling pathway reduced proliferation of CSC in vitro and in vivo but 
did not resulted in complete ablation of CSC indicating that IL6 signaling is an 
important but not the only determinant of the CSC phenotype. On the other hand, 
outgrowth of tumors from cells blocked for IL6 signaling might be a consequence of 
re-establishment of IL6 signaling pathway due to the long lasting in vivo experiment.  
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The results obtained from transformed normal mammary HME cells (see above) 
suggested that the deregulation of PI3K/Akt signaling effects expression of IL6 and 
IL6R. PI3K/Akt signaling is frequently deregulated in breast cancer (Adams et al., 
2011). Therefore, I tried to explore the effect of IL6 trans-signaling in MCF7 cells, 
which have constitutive active PI3K/Akt signaling due to a mutation in exon 9 of 
PIK3CA gene (Sanger-Institute, 2013). The assessment of IL6 and IL6R expression 
indicated low frequency of MCF7 cells expressing IL6 and IL6R and subsequent low 
protein expression. Surprisingly, activation of IL6 trans-signaling by HIL6 did not 
result in increased number of observed mammospheres suggesting IL6 trans-
signaling cannot add any significant stimulus in addition to the over-activation of 
PI3K/Akt pathway. Taken together, these data suggested that IL6 induced CSC 
phenotype via PI3K/Akt signaling.    
Recent data suggested the existence of a “equilibrium force” which coverts CnSC 
to CSC and vice versa (Gupta et al., 2009). Others argued that such conversion 
might be facilitated in cancer cells by induction of IL6 signaling (Iliopoulos et al., 
2011). The results presented in this work suggested that the underlying mechanism 
of the CSC to CnSC conversion and vice versa reflects the biology of normal adult 
mammary stem and progenitor cells where the stem cell phenotype might be 
influenced via autocrine/paracrine signals. The data are in line with a model where 
stromal cells may influence hierarchy of epithelial cells of an adult mammary gland 
via IL6 trans-signaling. This is of obvious relevance for the therapeutic implications of 
the CSC concept. The CSC proposes that only CSC can give rise to the disease 
relapse and metastasis and thus represent the only important therapy target which 
we currently miss. If however the CSC-CnSC hierarchy is not fixed, sole therapeutic 
eradication of CSC is unlikely to cure patients. 
Taken together, the presented data in this work suggest that IL6 signals in mammary 
cancer and normal cells via utilization of sIL6R employing IL6 trans-signaling. Normal 
and cancer mammary cells are able to express IL6 and sIL6R and therefore may 
utilize IL6 trans-signaling in an autocrine or paracrine way.  
In breast cancer cells IL6 trans-signaling resulted in increased proliferation of CSC. 
The results further indicated that IL6 trans-signaling induces stem cell characteristics 
via PI3K/Akt signaling pathway. 
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5. Summary 
The mammary gland is a paired, tubuloalveolar, exocrine gland which produces milk 
in females. The mammary gland is an inhomogeneous organ composed of epithelial 
derived ductal- alveolar structures responsible for milk production surrounded by 
connective tissue immersed in the lobes of adipose tissue. Mammary glands reach 
functional maturity at late pregnancy during a process known as lactation. During this 
process extensive proliferation and differentiation is enabled by adult mammary stem 
cells. Regulation of mammary cell phenotype and function is regulated by various 
signaling pathways which are activated as a result of the dynamic interaction 
between mammary cells and micro-environment. Deregulation of stem cell signaling 
pathways has been suggested to drive breast cancer by maintaining cancer stem 
cells (CSC), cells that give rise to all other cancer cell types detected within the tumor 
and contribute to an invasive phenotype observed in metastatic breast tumors. As 
normal stem cells, CSC interact with micro-environment and these interactions 
involve inflammatory cytokines such as Interleukin 6 (IL6).  
The aim of this work was to explore the effect of IL6 signaling in normal and 
malignant mammary stem and progenitor cells. Results indicated that activation of 
IL6 promotes proliferation of the normal and malignant stem and progenitor cells via 
mechanism know as IL6 trans-signaling. This mechanism is mainly activated via 
PI3K/Akt signaling. The obtained results suggested that the IL6 trans-signaling in 
normal mammary gland is activated in rather paracrine than autocrine way 
suggesting the role of mammary stromal cells in modulating hierarchy of epithelial 
cells. Indeed, the analysis of normal mammary gland indicated that fibroblasts, stem 
and progenitor cells but not terminally differentiated cells are able to trigger IL6 trans-
signaling and thus may prompt self-renewal and proliferation of adult mammary stem 
and progenitor cells. Moreover, the results indicated that cancer cells uti lize  
 IL6 trans-signaling and via paracrine signaling induce CSC phenotype of observed 
cells.  
Importantly, activation of IL6 trans-signaling resulted in acquisition of stem-like 
properties by normal progenitor cells. This is of obvious relevance for the therapeutic 
implications of the CSC concept. The CSC proposes that only CSC can give rise to  
5. Summary 
 
98 
 
the disease relapse and metastasis and thus represent the only important therapy 
target which we currently miss. If however the CSC-CnSC hierarchy is not fixed, sole 
therapeutic eradication of CSC is unlikely to cure patients.  
Altogether, IL6 signals in normal and malignant mammary cells via process known as 
trans-signaling. Paracrine and autocrine induced IL6 trans-signaling stimulates 
normal and malignant stem and progenitor cells and enables progenitor and CnSC to 
acquire stem-like cell phenotype. 
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1 AB- serum Human serum AB blood type 
2 ATCC American Type Culture Collection 
3 BCIP/NBT 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium 
4 bFGF Basic fibroblast growth factor 
5 bio-dUTP Biotin bound to deoxyuridine triphosphate 
6 BSA Bovine serum albumin 
7 cDNA Complementary DNA 
8 CK Cytokeratin 
9 CM Condition medium 
10 CSC Cancer stem cells 
11 DAPI 4',6-diamidino-2-phenylindole 
12 dATP 2'-deoxyadenosine 5'-triphosphate 
13 dCTP 2'-deoxycytidine 5'-triphosphate 
14 DfMD Differentiated mammary ducts 
15 dGTP 2'-deoxyguanosine 5'-triphosphate 
16 DMEM Dulbecco's Modified Eagle's Medium 
17 DMEM/F12 Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 
18 dNTP Deoxyribonucleotides 
19 DSL peptide Delta/Serrate/Lag-2 peptide 
20 dTTP 2′-deoxythymidine 5'-triphosphate 
21 EB buffer Elution buffer 
22 EDTA Ethylenediaminetetraacetic acid 
23 EF1-α Elongation factor 1 alpha 
24 EGF Epidermal growth factor 
25 EGFR Epidermal growth factor receptor 
26 EpCAM Epithelial cell adhesion molecule 
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27 FACS Fluorescence-activated cell sorting 
28 FCS Fetal calf serum 
29 g Gramm 
30 GFP Green fluorescent protein 
31 Gy Gray (SI unit for absorbed dose of ionizing radiation) 
32 H&E Hematoxylin and eosin 
33 HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
34 HIF Human immortalized fibroblasts 
35 HIL6 Hyper interleukin 6 
36 HME Human mammary epithelial  
37 IHC Immunohistochemistry 
38 IL6 Interleukin 6 
39 IL6R Interleukin 6 receptor 
40 LB medium  Liquid broth medium 
41 LRC Label retaining cells 
42 m-DIO Mouse iodothyronine deiodinase 
43 MEBM Mammary Epithelial Cell Growth Medium  
44 MFC Mammosphere forming capacity 
45 mg milligramme 
46 m-IVL Mouse involucrin 
47 ml milliliter 
48 MOI Multiplicity of infection 
49 MSM Basic mammosphere medium 
50 MUC1 Mucin 1 
51 nLRC Non label retaining cells 
52 non-CSC Non cancer stem cells 
53 NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
54 PBS Phosphate Buffer Saline 
55 PCR Polymerase chain reaction 
56 PFA Paraformaldehyde 
57 PIK3CA p110α protein 
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58 Polybrene Hexadimethrine bromide 
59 poly-HEMA Poly(2-hydroxyethyl methacrylate) 
60 PTEN Phosphatase and tensin homolog 
61 RPMI 1640 Roswell Park Memorial Institute medium 
62 RT Room temperature 
63 shPTEN short hairpin PTEN RNA 
64 sIL6R soluble interleukin 6 receptor 
65 SMA Smooth muscle actin 
66 TDLU Terminal duct lobular units 
67 TE buffer Tris/EDTA buffer 
68 THY1 Thymocyte differentiation antigen 1 
69 TNS Trypsin neutralizing solution 
70 tRNA Transfer ribonucleic acid 
71 µl Microliter 
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